 
 
 
 
 
 
 
A Randomized, Double -Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and 
Safety of Transitioning Subjects with Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or 
Continued Treatment with Rituxan¬Æ or MabThera¬Æ  
                                                                  NCT number: [STUDY_ID_REMOVED] 
                                                        Date of protocol : 10 July 2020  
CONFIDENTIAL  
All financial and nonfinancial support for this study will be provided by Dr. Reddy‚Äôs 
Laboratories  S.A. The concepts and information contained in this document or generated 
during the study are considered proprietary and may not be disclosed in whole or in part 
without the expressed, written consent of  Dr. Reddy‚Äôs Laboratories  S.A. 
The study will be conducted according to the International Council for  Harmoni sation  
Harmonised Tripartite Guideline E6(R2): Good Clinical Practice.  
Page 181
Dr. Reddy‚Äôs Laboratories S.A.  DRL_RI  
Protocol: RI-01-007 Version 3.0 Amendment 2  10 Jul 2020  
Protocol Approval ‚Äì Sponsor Signatory  
Study Title  A Randomized, Double-Blind, Parall el Group, Multicenter Study to 
Assess the Immunogenicity and Safety of Transitioning Subjects With 
Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan
¬Æ or MabThera¬Æ
Protocol Number  RI-01-007
Protocol Date  10 Jul  2020  
Protocol accepted and approved by:  
 
 
 
 
 
 
 
 
 
   
 		




	

Page 182
CI
CI
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : RI-01-007 Version 3.0 Amendment 2  10 Jul 2020 
Declaration of Investigator  
I have read and underst ood all sections of the protocol entitled ‚Äú A randomized, double -blind, 
parallel group, multicenter study to assess the immunogenicity and safety of transitioning 
subjects with rheumatoid arthritis to biosimilar rituximab (DRL_RI) or continued treatment 
with Rituxan¬Æ or MabThera¬Æ‚Äù and the accompanying Investigator‚Äôs Brochure. 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in accordance with the Final Protocol Version 3.0, Amendment 2, dated 10 Jul 2020, the 
International Council for Harmonisation Harmonised T ripartite Guideline E6(R 2): Good 
Clinical Practice and all applicable government regulations. I will not make changes to the protocol before consulting with Dr. Reddy‚Äôs Laboratories  S.A. or implement protocol changes 
without Independent E thics Committee /Institutional Review Board  approval except to 
eliminate an immediate risk to subject s. I agree to administer study treatment only to subjects 
under my personal supervision or the supervision of a sub- investigator.  
I will not supply the investigational drug to any person not authoriz ed to receive it. 
Confidentiality will be protected. Subject identity will not be disclosed to third parties or 
appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from Dr. Reddy‚Äôs Laboratories S.A . 
Signature of Principal Investigator  Date  
Name of Principal Investigator  
Page 184
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 6 Table of Contents  
Table of Contents .......................................................................................................................6  
List of Tables  ............................................................................................................................10  
List of Figures ..........................................................................................................................10  
Protocol Synopsis ..................................................................................................................... 11 
List of Abbreviations  ................................................................................................................18  
1 Introduction ......................................................................................................................21  
1.1 Background and Rationale ......................................................................................21  
1.1.1  Rituximab  .................................................................................................21  
1.1.1.1  Mechanism of Action  ...............................................................................22  
1.1.1.2  Pharmacodynamics ..................................................................................23  
1.1.1.3  Efficacy in Rheumatoid Arthritis  .............................................................24  
1.1.1.4  Safety Profile  ...........................................................................................26  
1.1.1.5  Immunogenicity  .......................................................................................27  
1.1.2  Dr. Reddy‚Äôs Rituximab (DRL_RI) ...........................................................28  
1.1.2.1  Nonclinical Studies  ..................................................................................29  
1.1.2.2  Clinical Studies  ........................................................................................29  
1.1.3  Study Rationale ........................................................................................30  
1.1.4  Risk/B enefit and Ethical Assessment  ......................................................30  
2 Study Objectives and Endpoints .......................................................................................31  
3 Investigational Plan  ..........................................................................................................32  
3.1 Study Design  ...........................................................................................................32  
3.1.1  Description  ...............................................................................................32  
3.1.2  Rationale of Study Design .......................................................................34  
3.1.3  Early Termination of the Study  ................................................................35  
3.1.4  End of Study ............................................................................................36  
3.2 Study Conduct During the COVID-19 Pandemic ...................................................36  
3.2.1  Benefit -Risk Assessment of Rituximab Treatment During the COVID -19 
Pandemic ..................................................................................................36  
3.2.2  Contingency Measures Taken During the COVID-19 Pandemic ............37  
4 Subject Selection and Withdrawal Criteria  ......................................................................39  
Page 185
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 7 4.1 Selection of Study Population .................................................................................39  
4.1.1  Inclusion Criteria  .....................................................................................39  
4.1.2  Exclusion Criteria  ....................................................................................39  
4.2 Withdrawal of Subjects From Study Treatment and/or the Study  ..........................42  
4.2.1  Reasons for Withdrawal/Discontinuation  ................................................42  
4.2.2  Handling of Withdrawals  .........................................................................43  
4.2.3  Replacements  ...........................................................................................44  
5 Study Treatments  ..............................................................................................................45  
5.1 Method of Assigning Subjects to Treatment Arms  .................................................45  
5.2 Treatments Administered  ........................................................................................45  
5.2.1  Study Treatment Infusion Preparation  .....................................................46  
5.2.2  Pre-medication for Study Treatment  Infusions ........................................46  
5.2.3  Study Treatment  Administration  ..............................................................46  
5.3 Identity of Investigational Product ..........................................................................48  
5.4 Management of Clinical Supplies  ...........................................................................48  
5.4.1  Packaging .................................................................................................48  
5.4.2  Labelling ..................................................................................................48  
5.4.3  Storage .....................................................................................................48  
5.4.4  Study Treatment Accountability  ..............................................................49  
5.5 Overdose Management  ...........................................................................................49  
5.5.1  Medi cation Errors  ....................................................................................50  
5.6 Transmission of Infectious Agents  ..........................................................................50  
5.7 Blinding ...................................................................................................................50  
5.7.1  Breaking the Blind  ...................................................................................51  
5.8 Treatment Compliance ............................................................................................51  
5.9 Prior and Concomitant Therapy ..............................................................................52  
5.9.1  Background Medication ...........................................................................52  
5.9.2  Other Concomitant Medication ...............................................................52  
6 Study Assessments and Procedures  ..................................................................................54  
6.1 Schedule of Assessments  ........................................................................................54  
6.1.1  Screening Period (Days -14 to 0) .............................................................54  
6.1.2  Treatment Period (2 W eeks)  ....................................................................56  
Page 186
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 8 6.1.3  Follow-Up Period (10 W eeks)  .................................................................58  
6.1.4  End of Study/Early Termination Visit (Week 12 ¬± 7 Days) .....................59  
6.1.5  Additional Follow- Up Visit (Week  26) ....................................................59  
6.2 Immunogenicity  Endpoint ......................................................................................60  
6.2.1  Immunogenicity  Sampling  .......................................................................60  
6.2.2  Immunogenicity  Assay  ............................................................................61  
6.3 Safety Assessments  .................................................................................................62  
6.3.1  Adverse Events ........................................................................................65  
6.3.1.1  Definitions ...............................................................................................65  
6.3.1.1.1  Adverse Event /Reaction  ...............................................................65  
6.3.1.1.2  Treatment -Emergent Adverse Event  ............................................67  
6.3.1.2  Recording of Adverse Events ..................................................................67  
6.3.1.3  Assessment of Severity  ............................................................................68  
6.3.1.4  Assessment of Causality  ..........................................................................69  
6.3.1.5  Reporting of Serious Adverse Events ......................................................71  
6.3.1.6  Suspected Unexpected Serious Adverse Reactions .................................72  
6.3.2  Abnormal Laboratory Values/Vital Signs 
Measurements/Electr ocardiograms ..........................................................73  
6.3.3  Deaths  ......................................................................................................73  
6.3.4  Clinical Laboratory Assessments  .............................................................74  
6.3.5  Physical Examination  ..............................................................................75  
6.3.6  Vital Sign Measurements  .........................................................................75  
6.3.7  12-L ead Electrocardiogram  .....................................................................75
6.3.8  Viral Disease Screening  ...........................................................................76  
6.4 Pregnancy ................................................................................................................76  
6.5 Blood Loss During the Study ..................................................................................77  
7 Statistical and Analytical Plan  ..........................................................................................78  
7.1  ........................................................................................78  
7.2 Analysis Sets ...........................................................................................................78  
7.3 Description of Subgroups to be Analyzed ..............................................................78  
7.4 Statistical Analysis Methodology ...........................................................................78  
7.4.1  General Principles  ....................................................................................78  
7.4.2  Missing Data ............................................................................................79  
7.4.3  Demographic and Baseline Characteristics  .............................................79  
Page 187
CI
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 9 7.4.4  Subject Disposition  ..................................................................................79  
7.4.5  Immunogenicity Analysis ........................................................................79  
7.4.6  Safety Analysis  ........................................................................................80  
7.4.7  Interim Analyses  ......................................................................................81  
8 Quality Control and Quality Assurance  ............................................................................82  
8.1 Case Report Forms/Source Data Handling  .............................................................82  
8.2 Data Management  ...................................................................................................82  
9 Ethics  ................................................................................................................................84  
9.1 Independent Ethics Committee or Institutional Review Board  ..............................84  
9.2 Ethical Conduct of the Study ..................................................................................84  
9.3 Subject Information and Consent  ............................................................................84  
10 Investigator‚Äôs Obligations ................................................................................................86  
10.1  Confidentiality  ........................................................................................................86  
10.2  Financial Disclosure and Obligations .....................................................................86  
10.3  Investigator Documentation ....................................................................................87  
10.4  Study Conduct .........................................................................................................87  
10.5  Adherence to Protocol .............................................................................................87  
10.6  Adverse Events and Study Report Requirements ...................................................87  
10.7  Records Retention  ...................................................................................................88  
10.8  Publications .............................................................................................................88  
11 Study Management ...........................................................................................................89  
11.1  Monitoring ..............................................................................................................89  
11.1.1  Monitoring of the Study ...........................................................................89  
11.1.2  Inspection of Records ..............................................................................89  
11.2  Management of Protocol Amendments and Deviations ..........................................90  
11.2.1  Protocol Amendments  ..............................................................................90  
11.2.2  Protocol Deviations/Violations  ................................................................90  
11.3  Study Termination  ...................................................................................................91  
11.4  Final Report ............................................................................................................91  
12 Financing and Insurance ...................................................................................................93  
Page 188
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 10 13 Reference List  ...................................................................................................................94  
14 Appendices .......................................................................................................................96  
14.1  Appendix 1: Schedule of Events .............................................................................96  
14.2  Appendix 2: Classification of Functional Status in Rheumato id Arthritis  .............98  
14.3  Appendix 3: Protocol Amendment ..........................................................................99  
14.3.1  Protocol Amendment 1 ‚Äì Protocol Version 2.0, Dated 12 Aug  2019 ......99  
14.3.1.1  Overview of Changes ...............................................................................99  
14.3.1.2  Changes to the Protocol Text .................................................................100  
14.3.2  Protocol Amendment 2 ‚Äì Protocol Version 3.0, Dated to be added .......105  
14.3.2.1  Overview of Changes .............................................................................105  
 
List of Tables  
Table  2-1  Objectives and Endpoints ............................................................................... 31  
Table  6-1: Blood Loss During the Study .......................................................................... 77  
Table  14-1  Schedule of Events  .......................................................................................... 96  
Table 14- 2: Classification of Functional Status in Rheumatoid Arthritis  .......................... 98  
 
List of Figures  
Figure 3-1  Study Scheme .................................................................................................. 34  
Figure 6- 1: Flow Diagram for the Evaluation and Characterization of Anti -Drug 
Antibodies ....................................................................................................... 62  
 
Page 189
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 11 Protocol Synopsis  
Protocol N umber:  RI-01-007 
Title:  A randomized, double -blind, parallel group, multicenter study to 
assess the immunogenicity and safety of transitioning subjects 
with rheumatoid arthritis to biosimilar rituximab  (DRL_RI) or 
continued treatment with Rituxan¬Æ or MabThera¬Æ 
Sponsor:  Dr. Reddy‚Äôs Laboratories  S.A. 
Elisabethenanlage 11 
CH-4051 Basel Switzerland  
Study Phase:  Phase 3 t ransition study  
Study S ites: It is planned that approximately 50 sites will be initiated for this 
study in up to 7 countries (including, but not restricted to , the 
United States  [US] ). 
Indication:  Rheumatoid arthritis  (RA)  
Rationale:  The evaluation of pharmacokinetics ( PK), efficacy, safety, and 
immunogenicity between a biosimilar and the innovator product 
is an essential component of an efficient clinical trial program collectively providing the evidence of biosimilarity.  
In the DRL_RI development program, Study RI -01-003 was a 
Phase 1/2, randomized, double -blind study comparing the PK  and 
pharmacodynamics (PD) of DRL_RI (biosimilar rituximab) with 
United S tates licensed rituximab ( Rituxan¬Æ, henceforth 
mentioned as US -rituximab ) and European Union (EU) -approved 
rituximab ( MabThera¬Æ, henceforth mentioned as EU -rituximab) 
in subjects with RA. Safety, efficacy , and immunogenicity of the 
treatments were also compared  to those of the innovator reference 
products in this study. The study met all pre  specified primary and 
secondary endpoints for PK, PD , and efficacy outcomes.  
The evaluation of safety and immunogenicity upon transition 
from a registered medicinal product to a biosimilar product is a 
requirement of US Food and Drug Administration. The objective 
of the current study is to assess the immunogenicity and safety of 
transitioning subjects with RA to DRL_RI from 
US-rituximab/EU -rituximab to continued treatment with 
US-rituximab/EU -rituximab. Subjects with RA who have 
received at least 1 full course comprising two 1000 mg infusions 
with either US -rituximab or EU -rituximab and are candidates for 
re-treatment with rituximab  will be enrolled .  
Page 190
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 12 During the initial phase of the clinical use of a newly introduced 
biosimilar product, it is expected that many subjects will 
experience a transition from the currently marketed reference 
product to the biosimilar. Hence, ruling out changes in the safety 
and immunogenicity of the product upon a single transition from the reference product to the potential 
biosimilar is a relevant 
element in the clinical evaluation of the latt er. 
Objectives:  ‚Ä¢ To assess the immunogenicity of transitioning subjects with 
RA to DRL_RI (biosimilar rituximab) from 
US-rituximab/EU -rituximab to continued treatment with 
US-rituximab/EU -rituximab. 
‚Ä¢ To assess the safety of transitioning subjects with RA to 
DRL_RI from US -rituximab/EU -rituximab to continued 
treatment with US -rituximab/EU -rituximab.  
Study Population:  Inclusion Criteria  
A subject will be eligible for enrolment in  the study if he/she 
meets all of the following criteria:  
1. Male or female subjects aged 18  years or older who have 
provided valid written informed consent. 
2. Subjects with a diagnosis of active RA who are eligible for the subsequent treatment course with US -rituximab  or 
EU-rituximab  
according to the clinical judgment of the 
investigator.  
3. Documented evidence that subject has received at least 1 full 
course comp rising two 1000 mg infusions of either 
US-rituximab  at least 16  weeks prior to the randomization 
visit or EU-rituximab  at least 24  weeks prior to the day of 
randomization visit. 
Note: Subjects are only eligible if they have received the prior 
US or EU -rituximab course within the 15 months prior to the 
date of randomization . 
4. Subjects receiving a stable dose of weekly methotrexate 
(MTX) for at least 4  weeks prior to randomization (between  
7.5 mg and 25 mg) and folic acid (at least 5  mg per week).  
Exclusion Criteria  
Subjects meeting any of the following criteria must not be 
enrolled in the study: 
1. Subjects with RA in functional Class IV  (Table 14-2). 
2. Subjects with human immunodeficiency virus  (positive 
HIV1Ab or HIV2Ab) , hepatitis B virus and/or hepatitis  C 
Page 191
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 13 virus infection , including th ose with positive results in the 
viral disease screening . 
3. Subjects with active tuberculosis  (TB) . Subjects with 
evidence of latent TB or a history of TB must have completed 
treatment or have initiated treatment for at least 1  month 
before the first dose of study treatment (Day  1). T B testing is 
required only if it is required by local regulations or practice.  
4. Active systemic infection.  
5. Severely immunocompromised. 
6. History of hypersensitivity to either US -rituximab  or 
EU-rituxima b or any of its excipients. 
7. Any serious illness or uncontrolled medical condition, 
including, but not limited to , severe infections, significant 
hepatic or renal disease, uncontrolled hypertension despite 
treatment (defined as blood pressure ‚â•160/95 mmHg),  
congestive heart failure (New York Heart Association 
[NYHA] Class III or IV), or other severe uncontrolled cardiac 
disease or uncontrolled diabetes with immediate risk of acute complications.  
8. Any condition that in the opinion of the investigator 
represent s an obstacle for study conduct and/or represents a 
potential unacceptable risk for subjects.  
9. Requir es treatment with any biological medicinal product 
during the study other than the study treatment. 
10. Previous treatment with B -cell modulating or cell -depleting 
biologic therapy, except US-rituximab  or EU -rituximab . 
11. Prior participation in this clinical trial or prior participation in 
any clinical trial with any monoclonal antibody within 
12 months of screening or prior participation in any clinical trial within 3  months of screening or within 5 half -lives of the 
investigational drug or until the expected PD effect has 
returned to baseline, whichever is longer. 
12. Treatment with other biologic disease -modifying  
anti-rheumatic drugs, or J anus kinase (JAK)  inhibitors 
administered within 12  weeks before the first dose of 
rituximab of the prior treatment course onwards till the date 
of randomization. 
13. Subjects with the following laboratory abnormalities: 
‚Ä¢ Subjects with screening total white blood c ell count 
<3000/Œº L, platelets <100,000/ ŒºL, neutrophils <1500/ ŒºL, 
or hemoglobin <8.5 g/dL. 
Page 192
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 14 ‚Ä¢ Abnormal liver function tests such as aspartate 
aminotransferase, alanine aminotransferase, or alkaline 
phosphatase >2 √ó upper limit of normal (ULN) . A single 
parameter >2  √ó ULN can be re -checked as soon as 
possible, at least prior to randomization, if required per the 
investigator‚Äôs discretion . 
‚Ä¢ Creatinine clearance ( Cockcroft & Gault formula) of less 
than 50 mL /min. 
14. History of vaccination with live vaccines within 4 weeks of 
the first dose of study treatment  (Day  1) or known to require 
live vaccines during the study. 
15. Lactating or pregnant female.  
16. Women of childbearing potential (WOCBP) who do not 
consent to use highly effective methods of birth control during 
treatment and for at least 12  months after the last 
administration of study treatment. 
Note:  Per the Clinical Trial Facilitation Group (CTF G) 
guidelines 2014, a wom an is considered of childbearing 
potential if fertile, following menarche until becom ing 
postmenopausal (i.e., no menses for 12 months without an 
alternative medical cause) unless permanently sterile through 
hysterectomy, bilateral salpingectomy , and bilateral 
oophorectomy). Highly effective birth control measures per 
CTFG guidelines 2014 include the following : 
‚Ä¢ combined (estrogen and progestogen containing) 
hormonal contraception associat ed with inhibition of 
ovulation - oral, intravaginal, and transdermal 
‚Ä¢ progestogen- only hormonal contraception associat ed 
with inhibition of ovulation - or al, injectable, 
implantable  
‚Ä¢ intrauterine device  
‚Ä¢ intrauterine hormone -releasing system  
‚Ä¢ bilateral tubal occlusion  
‚Ä¢ vasectomised partner  
‚Ä¢ sexual abstinence  
Site should advi se subjects to use any of the methods listed 
above, or per the country /site-specific requirement s. 
17. Sexually active male subjects unless permanently sterile by 
bilateral orchidectomy, who do not agree to use 1 of the highly 
effective methods of birth control  listed in Exclusion Criterion 
Page 193
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 15 #16 during treatment and for at least 12  months after the last 
administration of study treatment.  
18. Subject with serum IgG < lower limit of normal  
Study D esign:  This is a randomized, double -blind, parallel group , multicenter, 
Phase 3 transition study. 
A course of treatment with US -rituximab  or EU-rituximab  in RA 
consists of two 1000 mg intravenous (IV) infusions separated by 
2 weeks. Subjects with RA who have received at least 1 full 
course comprising two 1000 mg infusions with either 
US-rituximab  or EU-rituximab  will be eligible fo r the study. For 
this prior course of treatment, subjects will have received either US-rituximab  or EU -rituximab . 
Subjects will then be randomized by an interactive web r esponse 
system  (IWRS) to receive either two 1000  mg infusions of 
DRL_RI  (Arm A) or US -rituximab /EU-rituximab  (Arm B) on 
Day 1 and Day 15. This will constitute the next course of 
rituximab treatment.  Subjects randomized to Arm  A will receive 
DRL_RI and subjects randomized to Arm  B will continue to 
receive either US -rituximab or EU -rituximab . The rituximab 
reference product (US-licensed rituximab [Rituxan] or 
EU-approved rituximab [Mabthera ]) used should be the same in 
the prior and the randomized treatment course, respectively. 
Subjects having received the prior treatment course with reference 
products other than US -licensed rituximab (Rituxan) or 
EU-approved rituximab (Mabthera) will not be eligible for the 
study. Subjects should not be switched from the prior to the 
randomized treatmen t course from US -licensed to EU -approved 
reference product or vice versa. 
The study will consist of a screening period (Days  -14 to 0) and a 
double-b lind period (Day  1 to Week 12). Subjects will attend a 
screening visit followed by visit s at Week s 0 (Day  1), 2, 4, 8, and 
12 (e nd of study [EOS])  after randomization.  An additional 
follow -up visit will be conducted at  Week  26 to evaluate safety 
and to perform a serum pregnancy test in WOCBP .  
Subjects having signed the informed consent form  versions prior 
to the one introduced by this amendment  need to re -consent to 
continue participating in the study after Week  12 through 
Week  26. If a subject does not re -consent for further study 
participation after Week  12, then his/her study data up to W eek 12 
will be collected and the subject will be discontinued from the study. 
Page 194
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 18 List of Abbreviations  
Abbreviation Definition  
ACR  American College of Rheumatology  
ADA  Anti-drug Antibody 
ADL  Activities of D aily L iving  
ADR  Adverse Drug R eaction  
AE Adverse Event 
Anti-CCP  Anti-citrullinated P eptide  
AUC  Area Under The Concentration-t ime Curve  
AUC 0-t AUC from Time Zero to the Last Quantifiable Time Point  
Œ≤-hCG Beta Human Chorionic Gonadotropin 
BP Blood Pressure  
C1q C1 q Subcomponent 
CD Cluster of Differentiation  
CDC  Complement-dependent Cytotoxicity  
CFR  Code of Federal Regulations 
CI Confidence Interval  
COVID-19 Coronavirus D isease - 2019 
CRO  Clinical Research Organization  
CRP  C-reactive Protein  
CSR  Clinical Study Report 
CTCAE  Common Terminology Criteria for Adverse Events  
CTFG  Clinical Trial Facilitation Group  
DAS 28 Disease Activity Score  
DMARD  Disease-modifying A nti-rheumatic Drug 
DRL_RI  Biosimilar Rituximab  
DVD  Digital Versatile Disc  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
ELISA  Enzyme-linked Immunosorbent Assay 
EOS  End of Study 
ET Early Termination  
EU European Union 
Page 197
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 19 Abbreviation Definition  
EULAR  European League Against Rheumatism 
Fc Fragment Crystallizable  
FDA  Food and Drug Administration 
FSH Follicle -stimulating Hormone 
GCP  Good Clinical Practice  
HACA  Human Anti-chimeric antibody 
HAQ -DI Health Assessment Questionnaire Disability Index  
HBcAb  Hepatitis B Core Antibody 
HBsAg  Hepatitis B Surface Antigen  
HCV  Hepatitis C Virus 
HIV Human immunodeficiency virus 
IB Investigator‚Äôs Brochure  
ICF Informed Consent Form 
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
Ig Immunoglobulin  
IgA Immunoglobulin A  
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IRB Institutional Review Board  
IRR Infusion- related Reaction  
IV Intravenous  
IWRS  Interactive Web Response System  
JAK Janus Kinase  
LLN  Lower Limit Of Normal  
mAb  Monoclonal Antibody 
MCID  Minimal Clinically Important Difference  
MedDRA  Medical D ictionary for Regulatory A ctivities  
MTX  Methotrexate 
NAb  Neutralizing Antibody 
NCI National Cancer Institute  
NHL  Non-Hodgkin‚Äôs Lymphoma  
Page 198
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 20 Abbreviation Definition  
PD Pharmacodynamic(s) 
PEI Paul Ehrlich Institute  
PI Prescribing  Information  
PK Pharmacokinetic (s) 
QTc Corrected QT Interval 
RA Rheumatoid Arthritis  
RF Rheumatoid Factor  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAS Statistical Analysis System  
SmPC  Summary of Product Characteristics  
SOP Standard Operating Procedure  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TB Tuberculosis 
TEAE  Treatment -emergent Adverse Event  
TNF  Tumor Necrosis Factor  
ULN  Upper Limit Of Normal  
US United States  
WOCBP  Women of Childbearing Potential  
 
Page 199
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 21 1 Introduction  
Rituximab is licensed in the United States  (US)  as Rituxan¬Æ and approved in the European 
Union (EU)  as MabThera¬Æ, for use in B -cell non-Hodgkin‚Äôs l ymphoma (NHL), chronic 
lymphocytic leukemia, rheumatoid arthritis (RA) in combination with methotrexate  (MTX)  in 
adult patient s with moderately  to severely  active RA who had an inadequate response to 1 or 
more tumor necrosis factor (TNF) antagonist therapies, granulomato sis with polyangiitis and 
microscopic polyangiitis in combination with glucocorticoids , and m oderate to severe 
pemphigus vulgaris (Rituxan prescribing information  [PI] 2020, MabThera Summary of 
Product Characteristics [ SmPC ] 2020 ). Rituxan is the commercially available product in the 
US and will be referred to as US -rituximab; MabThera is the commercially available product 
in the EU and will be referred to as EU -rituximab  in the protocol . Rituximab biosimilar 
(hereafter , referred to as DRL_RI) is being developed as a potential biosimilar to US -rituximab 
and EU- rituximab.  
The term ‚Äúbiosimilar‚Äù refers to a biologic drug that is developed to be similar to an existing 
licensed or approved reference product  or reference medicinal product. Biosimilars are 
intended to treat the same diseases as the reference product /reference med icinal product using 
the same dose and treatment regimen. Biosimilars are structurally highly similar to their 
reference product s, and minor differences caused by the manufacturing process have no 
clinically meaningful effect on the pharmacokinetics (PK), safety, immunogenicity, or efficacy of the biosimilar compared with  the reference product/reference medicinal product. 
In the DRL_RI development program, the primary objective in Study RI -01-003 
(Section  1.1.2.2) was to compare the plasma PK profiles of DRL_RI with US-rituximab  and 
EU-rituximab ; secondary objectives were to compare the pharmacodynamics (PD), efficacy, 
safety, and immunogenicity of DRL_RI  with US-rituximab  and EU -rituximab . The objective 
of the current study is to assess the immunogenicity and safety of transitioning subjects with 
RA to DRL_RI from US -rituximab /EU-rituxim ab to continued treatment with 
US-rituximab /EU-rituximab . 
1.1 Background and Rationale  
1.1.1 Rituximab 
Rituximab is a genetically engineered chimeric murine/human monoclonal immunoglobulin 
(Ig) G1 kappa antibody directed against the B- lymphocyte antigen cluster of differentiation  
Page 200
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 22 (CD) 20. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM 
(Rituxan PI 20 20, MabThera SmPC 20 20). 
Rituximab is approved for use in NHL, chronic lymphocytic leukemia, RA, granulomatosis 
with polyangiitis, microscopic polyangiitis , and moderate to severe pemphigus vulgaris (this 
indication is currently approved in the United States , but not in the European Union). Further 
information is contained within both the PI  of US -rituximab and public information including 
the SmPC  for EU -rituximab  (Rituxan PI 20 20, MabThera SmPC 20 20). 
Multiple clinical trials have been conducted to support the approval of rituximab for the 
treatment of  RA. Rituximab in combination with MTX is indicated for the treatment of adult 
patients with moderately to severely active RA who had an inadequate response to 1 or more 
TNF antagonist therapies  (Rituxan PI 20 20, MabThera SmPC 20 20). 
1.1.1.1  Mechanism of Action  
Rituximab binds specifically to the transmembrane an tigen, CD20, a non-glycosylated 
phosphoprotein, located on pre -B and mature B lymphocytes. The antigen is expressed on 
>95% of all B -cell NHLs. CD20 is found on both normal and malignant B -cells, but not on 
hematopoietic stem cells, pro -B-cells, normal plasma cells, or other normal tissue (s). This 
antigen does not internalize upon antibody binding and is not shed from the cell surface. CD20 
does not circulate in the plasma as a free antigen and thus, does not compete for antibody 
binding ( MabThera  SmPC 20 20). 
The fragment antigen -binding domain of rituximab binds to the CD20 antigen on 
B lymphocytes and the fragment crystallizable  (Fc) domain can recruit immune effector 
functions to mediate B -cell lysis. Mechanisms of effector -mediated cell lysis include 
complement- dependent cytotoxicity (CDC)  resulting from complement component  
C1 q subcomponent ( C1q) binding, and antibody- dependent cellular cytot oxicity mediated by 
1 or more of the Fc Œ≥ receptors on the surface of granulocytes, macrophages, and natural killer  
cells. Rituximab binding to CD20 antigen on B  lymphocytes has also been demonstrated to 
induce cell death via apoptosis ( MabThera SmPC 20 20). 
Rheumatoid arthritis  is an immune -mediated disease of the joints that is characteri zed by 
chronic inflammation and synovial hyperplasia that  eventually leads to cartilage and bone 
destruction  (Komatsu and Takayanagi 2012 ). Current treatments include disease -modifying 
Page 201
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 23 anti-rheumatic drugs (DMARDs), tofacitinib, glucocorticoids, etc.  (Singh et al 2016 ). B-cells 
are believed to play a role in the pathogenesis of RA and associated chronic synovitis. In this 
setting, B -cells may be acting at multiple sites in the autoimmune/inflammatory process, 
including th orough production of rheumatoid factor (RF) and other autoantibodies, antigen 
presentation, T -cell activation, and/or pro- inflammatory  cytokine production ( Rituxan  PI 
2020). 
Administration of rituximab in RA patients results in almost  complete depletion of peripheral 
B-cells and  variable depletion of B -cells in synovium and other sites such as lymphoid tissue 
and bone  marrow . The degree of B -cell depletion in the peripheral  blood and synovium has 
been correlated positively with the clinical response of rituximab  (Mok CC  2014, Cohen MD  
and Keystone E 2015). 
1.1.1.2 Pharmacodynamics 
In RA patients, immediate depletion of B -cells in the peripheral blood was observed following 
2 infusions of 1000 mg rituximab separated by a 14 -day interval. The majority of patients 
demonstrat ed near complete depletion (CD19 counts below the lower limit of quantification, 
20 cells/¬µ L) within 2  weeks after receiving the first dose of rituximab. The majority of patients 
showed peripheral B -cell depletion for at least 6  months. A small proportion of  patients (~4%) 
had prolonged peripheral B -cell depletion lasting more than 3  years after a single course of 
treatment. Peripheral blood B -cell counts bega n to increase from Week  24 (during the 
follow-up p eriod) and evidence for repopulation was observed i n the majority of patients by 
Week  40 (Dr. Reddy‚Äôs Laboratories Investigator‚Äôs Brochure [IB]). 
Total serum Ig levels, i mmunoglobulin M ( IgM), i mmunoglobulin G ( IgG), and 
immunoglobulin A ( IgA) were decreased at 6 months with the largest change observed in IgM. 
At Week  24 of the first course of rituximab  treatment, small proportions of patients experienced 
decrease in IgM (10%), IgG (2.8%), and IgA (0.8%) levels below  the lower limit of normal  
(LLN) . In the experience with rituximab  in RA patients during repeated rituximab  treatment, 
23.3%, 5.5%, and 0.5% of patients experienced decreases in IgM, IgG, and IgA , respectively 
concentrations below the LLN  at any time after receiving rituximab . The clinical consequences 
of decrease  in Ig levels in RA patients treated with rituximab  are unclear  (Dr. Reddy‚Äôs 
Laborator ies IB). 
Page 202
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 24 Treatment with rituximab in patients with RA was associated with reduction of certain 
biologic al markers of inflammation such as interleukin -6, C-reactive protein  (CRP) , serum 
amyloid protein, S100 A8/S100 A9 heterodimer complex, anti -citrullinated peptide  (anti- CCP), 
and RF ( Dr. Reddy‚Äôs Laborator ies IB). 
1.1.1.3 Efficacy in R heumatoid A rthritis  
The efficacy and safety of rituximab in alleviating the symptoms and signs of RA in subj ects 
with an inadequate response to TNF inhibitors was demonstrated in a pivotal randomized, controlled, double -blind, multicenter study. The study evaluated 517 RA subjects who had 
experienced an inadequate response or intolerance to 1 or more TNF inhibitor therapies. 
Rituximab was administered as 2 intravenous (IV) infusions separated by an interval of 15 days. 
Subjects received two 1000 mg IV infusions of rituximab or placebo in combination with MTX. All subjects received concomitant 60 mg oral prednisone on Days  2 to 7 and 30 mg on Days  8 
to 14 following the first infusion. The primary endpoint was the proportion of subjects who 
achieved at least 20% improvement in American College of Rheumatology (ACR) score 
(ACR20) at Week  24. Subje cts were followed beyond Week  24 for long- term endpoints, 
including radiographic assessment at 56 weeks and at 104 weeks. During this time, 81% of 
subjects from the original placebo group received rituximab between Week  24 and Week  56, 
under an open- label extension study protocol ( MabThera  SmPC 20 20). 
Disease Activity O utcomes  
Rituximab in combination with MTX significantly increased the proportion of subjects 
achieving ACR20 compared with subjects treated with MTX alone. Clinically and statistically , 
significant improvement was also noted i n all individual components of the ACR response 
(tender and swollen joint counts, subject and physician global ass essment, Health Assessment 
Questionnaire Disability Index [HAQ -DI], pain assessment, and C RP). Subjects treated with 
rituximab in combination with MTX had a significantly greater reduction in Disease Activity Score  28 (DAS28) than subjects treated with MTX  alone. Similarly, a good to moderate 
European League Against Rheumatism (EULAR) response was achieved by significantly more 
subjects treated with rituximab and MTX compared to subjects treated with MTX alone  
(MabThera SmPC 20 20). 
Page 203
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 25 Radiographic Response  
Structural joint damage was assessed radiographically and expressed as change in modified 
total sharp score and its co mponents, the erosion score , and joint space narrowing score. 
Subjects with inadequate response or intolerance to 1 or more TNF inhibitor therapies, 
receiving rituximab in combination with MTX demonstrated significantly less radiographic 
progression than subjects originally receiving MTX alone at 56 weeks. Of the subjects 
originally receiving MTX alone, 81% received ri tuximab either as a rescue between Week  16 
to Week  24 or in the extension trial before Week 56. A higher proportion of subjects receiving 
the original rituximab/MTX treatment also had no erosive progression over 56 weeks 
(MabThera  SmPC 20 20). 
Inhibition of the rate of progressive joint damage was also observed long term. Radiographic analysis at 2  years demonstrated significantly reduced progression of structural joint damage 
in subjects receiving rituximab in combination with MTX compared to MTX alone as well as a significantly higher proportion of subjects with no progression of joint damage over the 
2-year period  (MabThera SmPC 20 20). 
Physical Function and Quality of Life Outcomes  
Significant reductions in HAQ -DI and fatigue ( Functional Assessment of Chronic Illness 
Therapy-Fatigue [FACIT -F]) scores were observed in subjects treated with rituximab 
compared to subjects treated with MTX alone. The proportions of rituximab- treated subjects 
showing a minimal clinically important difference (M CID) in HAQ -DI (defined as an 
individual total score decrease of >0.22) was also higher than among subjects receiving MTX alone ( MabThera SmPC 20 20). 
Significant improvement in health -related  quality of life was also demonstrated with 
significant improvement in both the physical health score and mental health score of the Short 
Form  36 (SF-36) Health Survey. Further, a significantly higher proportion of  subjects achieved 
MCIDs for these scores ( MabThera SmPC 20 20). 
Efficacy in Autoantibody (RF and/or anti- CCP) Seropositive Subjects  
Subjects seropositive to RF and/or anti -CCP who were treated with rituximab in combination 
with MTX showed an enhanced response compared with  subjects negative to both. Efficacy 
Page 204
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 26 outcomes in rituximab -treated subjects were analyzed based on autoantibody status prior to 
commencing treatment. At Week  24, subjects who were seropositive to RF and/or anti -CCP at 
baseline had a significantly increased probability of achieving ACR20 and ACR50 responses 
compared to seronegative subjects ( P=0.0312 and P =0.0096). Thes e findings were replicated 
at Week  48, where autoantibody seropositivity also significantly increased the probability of 
achieving ACR70. At Week 48, seropositive subjects were 2 to 3  times more likely to achieve 
ACR responses compared to seronegative subjects. Seropositive subjects also had a 
significantly greater decrease in DAS28 -erythrocyte sedimentation rate  compared to 
seronegative subjects ( MabThera  SmPC 20 20). 
Long -Term Efficacy With Multiple Course Therapy  
Treatment with rituximab in combination with MTX over multiple courses resulted in sustained improvements in the clinical signs and symp toms of RA, as indicated by ACR, 
DAS28 -erythrocyte sedimentation rate , and E ULAR  responses, which were evident in all 
subject populations studied. Sustained improvements in physical function as indicated by the HAQ- DI score and the proportion of subjects achieving MCID for HAQ -DI were observed  
(MabThera SmPC 20 20). 
Other clinical studies conducted to demonstrate the efficacy of rituximab in RA subjects had 
similar results  (Mok CC  2014, Cohen MD and Keystone E 2015, and Rituxan  PI 20 20). 
1.1.1.4 Safety Profile 
The overall safety profile of rituximab in RA is based on data from patients from clinical trials and from post -marketing  surveill ance (MabThera SmPC 20 20). 
In clinical trials more than 3100  subjects received at least 1 treatment course and were followed 
for periods ranging from 6 months to over 5 years; approximately 2400 subjects received 2 or 
more courses of treatment with over 1000 having received 5 or more courses. The safety 
information collected during post- marketing  experience reflects the expected adverse reaction 
profile as seen in clinical trials for rituximab  (MabThera  SmPC 20 20). 
The most frequent adverse drug reactions (ADRs) following receipt of rituximab in clinical studies were infusion -related reactions (IRRs). Among the 3189 subjects treated with 
rituximab, 1135 (36%) experienced at least 1 IRR with 733/3189 subjects (23%) experiencing 
an IRR following first infu sion of the first exposure to rituximab. The incidence of IRRs 
Page 205
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 27 declined with subsequent infusions. In clinical trials, fewer than 1% (17/3189) of subjects 
experienced a serious IRR. There were no common terminology c riteria for adverse events  
(CTCAE) Grade 4 IRRs and no deaths due to IRRs in the clinical trials. The proportion of CTCAE Grade  3 events and of IRRs leading to withdrawal decreased by course, and such 
events were rare from Course 3 onwards. Pre -medication with IV glucocorticoid sign ificantly 
reduced the incidence and severity of IRRs. Severe IRRs with fatal outcome have been reported 
in the post marketing setting  (MabThera SmPC 20 20). 
Other ADRs reported in greater than 10% of subjects in clinical studies or during post -marking 
surveillance in patients with RA receiving rituximab included upper respiratory tract infection, 
urinary tract infection, headache, and decreased IgM levels ( MabThera SmPC  2020). 
The overall rate of infection was approximately 94 per 100 patient -years in rituximab -treated 
patients. The infections were predominately mild to moderate and consisted mostly of upper 
respiratory tract infections and urinary tract infections. The incidence of infections that were 
serious or required IV antibiotics was approximately 4 per 100 patient -years. Cases of 
progressive multifocal leukoencephalopathy with fatal outcome have been reported following use of rituximab for the treatment of autoimmune diseases , including RA. Reactivation of 
hepatitis  B infection has also been very rarely reported in RA patients receiving rituximab  
(MabThera SmPC 20 20). 
Multiple courses of treatment are associated with a similar ADR profile to that observed following first exposure. The rate of all ADRs following first rituximab exposure was highest 
during the first 6  months and declined thereafter. This is mostly accounted for by IRRs (most 
frequent during the first treatment course), RA exacerbation , and infections, all of which were 
more frequent in the first 6  months of treatment ( MabThera SmPC 20 20). 
1.1.1.5 Immunogenicity  
As rituximab is a chimeric monoclonal antibody  (mAb), the development of human 
anti-chimeric antibodies (HACAs) lower the level of the drug and hence, its clinical efficacy 
is a concern  (Mok CC  2014). 
A pooled analysis on the long- term safety of rituximab  in clinical trials (2578  subjects) 
revealed that HACAs were present in 11% of subjects on at least 1 visit. There was no obvious 
relationship between the dose of rituximab used (500 mg versus 1000 mg) and the incidence 
Page 206
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 28 of the HACA response. The presence of HACAs to rituximab does not appear to affect the 
efficacy of rituximab in depleting B -cells, clinical efficacy at the study endpoints, and 
re-treatment efficacy. There is also no obvious relationship between the HACA response and 
the occurrence of infusion reactions to rituximab  (Mok CC  2014). 
1.1.2 Dr. Reddy‚Äôs Rituximab (DRL_RI)  
Dr. Reddy‚Äô s Laboratories  S.A. ( DRL ) is developing a proposed biosimilar version of the 
chimeric anti- CD20 mAb , rituximab  (DRL_RI).  
DRL_RI is a chimeric human/murine IgG1 kappa mAb  consisting of murine light and heavy 
chain variable regions and human constant region sequences. The molecule is composed of 2 heavy chains of 451 amino acids each and 2 light chains of 213 amino acids each with a 
molecular weight of 145  kilodaltons . Each of the heavy chains contains 1 N-linked glycan 
(resulting in 2 N-linked glycans per molecule). 
The primary amino acid sequence is identical and the secondary and tertiary structures of DRL_RI are indistinguishable from the reference product s (US-rituximab  and EU-rituximab ) 
when compared by a battery of orthogonal analytical methods. The glycosylation variants (glycoforms) of DRL_RI are the same as tho se found in the r eference product s, and the 
proportions of each of the glycoforms are similar between the 3 proteins. 
Further information can be found in the IB for DRL_RI  (Dr. Reddy‚Äôs Laborator ies IB). 
Page 207
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 29 1.1.2.1  Nonclinical Studies  
In Vitro Pharmacology  
The comparison of in vitro functional activities of DRL_RI, US -rituximab , and EU-rituximab  
were performed using multiple cell -based and binding assays. Batches of DRL_RI, 
US-rituximab , and EU-rituximab  were compared using 2 one-s ided t -test analyses. A 
difference of 20% in the mean relative binding or potency was deemed acceptable. The  
complement dependent cytotoxicity (CDC ) and the  antibody- dependent cell -mediated 
cytotoxicity  (ADCC) activities and the binding of DRL_RI, US -rituximab , and EU-rituximab  
to CD20, C1q, Fc Œ≥RI, Fc Œ≥RIIa, Fc Œ≥RIIb, Fc Œ≥RIII, and FcRn were found to be similar. 
Therefore, DRL_R I, US-rituximab , and EU-rituximab  are considered similar in terms of their 
in vitro functional characteristics  (Dr. Reddy‚Äôs Laboratories IB ). 
1.1.2.2  Clinical Studies  
Study RI -01-003 was a Phase 1/2, randomized, double -blind study, conducted in subjects with 
RA to compare PK, PD, efficacy, safety, and immunogenicity of DRL_RI  with US-rituximab  
and EU- rituximab .  
The PK endpoint results showed that the 91% confidence interval ( CI) for the geometric mean 
of the test to reference ratios of all endpoints were within the pre  specified similarity 
acceptance range of 80.00% to 125.00% for the comparisons of DRL_RI with  EU-rituximab  
and US-rituximab , and for the comparison of EU -rituximab  with US-rituximab , demonstrating 
the PK similarity of the 3  products. The primary PK endpoints were area under the 
concentration -time curve (AUC) from time zero extrapolated to infinity for both study 
treatment infusions, AUC from start to the first infusion to the second infusion on D ay 14 after 
the first infusion , and AUC from time zero to the last quantifiable time point (AUC 0-t) after the 
second infusion of study treatment . The secondary PK endpoints were AUC 0-t over the entire 
treatment course and maximum plasma concentration (C max after the first and after the second 
infusion. Results from the secondary endpoints of Study RI -01-003 also showed that the safety 
and immunogenicity profiles; CD20- positive peripheral  blood B -cell count reductions; the 
proportion of subjects meeting the ACR20, ACR 50, and ACR70 improvement criteria from 
baseline to Week  24; and the mean change from baseline to Week 24 in DAS 28-C RP, were all 
comparable across DRL_RI, US-rituximab , and EU -rituximab.  
Page 208
CI
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 30 1.1.3 Study Rationale  
The evaluation of PK, efficacy , safety , and immunogenicity between a biosimilar and the 
innovator product is an essential component of an efficient clinical trial program c ollectively 
providing the evidence of biosimilarity. In the DRL_RI development program, 
Study RI -01-003 was a Phase 1/2, randomized, double -blind study comparing the PK and PD 
of DRL_RI with US-rituximab and EU -rituximab in subjects with RA. Safety, efficacy , and 
immunogenicity of the treatments were also compared to those of the innovator reference 
products in this study. The study met all pre  specified primary and secondary endpoints for PK, 
PD, and efficacy outcomes ( Section  1.1.2.2).  
The evaluation of safety and immunogenicity upon transition from a registered medicinal 
product to a biosimilar product is a requirement of US Food and Drug Administration ( FDA). 
The objective of the current study is to assess the immunogenicity and safety of transitioning 
subjects with RA to DRL_RI from US -rituximab/EU -rituximab to continued treatment wi th 
US-rituximab/EU -rituximab. Subjects with RA , who have received at least 1 full course 
comprising two 1000 mg infusions with either US -rituximab or EU-rituximab and are 
candidates for re- treatment with rituximab , will be enrolled. 
During the initial phas e of the clinical use of a newly introduced biosimilar product, it is 
expected that many patients will experience a transition from the currently marketed reference 
product to the biosimilar. Hence, ruling out changes in the safety and immunogenicity of the 
product upon a single transition from the reference product to the potential biosimilar is a 
relevant element in the clinical evaluation of the lat ter. 
1.1.4 Risk/Benefit and Ethical Assessment  
There is a substantial body of data  related to the safety and efficacy of 
US-rituximab/EU -rituximab in subjects with RA (FDA, Rituxan PI/European Medicines 
Agency MabThera SmPC ) (Rituxan  PI 20 20, MabThera  SmPC 20 20). Preliminary results of a 
comprehensive head -to-head comparison of DRL_RI to the US -rituximab  and the 
EU-rituximab  has demonstrated that DRL_RI is similar to the reference product s 
(Section 1.1.2). Thus, the risk/benefit of DRL_RI  is expected to be comparable to that of 
US-rituximab/EU -rituximab. 
More detailed information about the known and expected benefits/risks and expected adverse 
events (AEs) of DRL_RI may be found in the IB for DRL_RI ( Dr. Reddy‚Äôs Laborator ies IB). 
Page 209
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 31 2 Study Objectives  and Endpoints  
Table  2-1 Objectives and Endpoints  
Objectives  Endpoints  
To assess the immunogenicity of transitioning subjects 
with RA  to DRL_RI (biosimilar rituximab) from 
US-rituximab/EU -rituximab to continued treatment 
with US-rituximab/EU -rituximab . The immunogenicity endpoint is:  
The incidence of anti -drug antibodies  (ADA), 
includ ing titer and neutralizing antibodies  (NAb). 
To assess the safety of transitioning subjects with RA  
to DRL_RI from US-rituximab/EU -rituximab  to 
continued treatment with US -rituximab/EU -rituximab . The primary safety endpoints are: 
‚Ä¢ Incidence of treatment -emergent adverse events  
(TEAEs) and serious adverse events  (SAEs). 
‚Ä¢ Incidence of anaphylactic reactions, 
hypersensitivity reactions, and IRRs. 
Other safety endpoints are: 
‚Ä¢ Clinical laboratory parameters  
‚Ä¢ Vital signs  
‚Ä¢ Twelve -lead electrocardiogram s (ECG) 
‚Ä¢ Physical examination  
Abbreviations: EU, European Union; IRR, infusion -related reactions ; RA, rheumatoid arthritis; US, United  
States.  
 
Page 210
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 32 3 Investigational Plan  
3.1 Study Design  
3.1.1 Description  
This is a randomized, double -blind, parallel group, multicenter, Phase 3 transition study in 
subjects with active RA who are eligible for the subsequent treatment course with 
US-rituximab or EU- rituximab according to the clinical judgment of the investigator . 
It is planned to randomize 140 subjects (70 per treatment arm) at approximately 50 site s in up 
to 7 countries (including, but not restricted to the United S tates). 
A course of treatment with US -rituximab or EU -rituximab in RA consists of two 1000 mg IV 
infusions separated by 2 weeks. Subjects with RA who have received at least 1 full course 
comprising two 1000 mg infusions with either US -rituximab or EU -rituximab will be eligible 
for the study. The rituximab reference product ( US-licensed rituximab [ Rituxan ] or 
EU-approved rituximab [Mabthera] ) used should be the same in the prior and the randomized 
treatment course , respectively . Subjects having received the prior treatment course with 
reference products other than US -licensed rituximab (Rituxan) or EU -approved rituximab 
(Mabthera) will not be eligible  for the study. Subjects should not be switched from the prior to 
the randomized treatment course from US -licensed to EU -approved reference product or vice 
versa.  
Subjects will then be randomized by interactive web response system ( IWRS ) to receive either 
two 1000 mg infusions of DRL_RI (Arm A) or US -rituximab/EU -rituximab (Arm B) on Day  1 
and Day 15. This will constit ute the next course of rituximab treatment. Subjects randomized 
to Arm A will receive DRL_RI and subjects randomized to Arm  B will continue to receive 
either US -rituximab or EU -rituximab.  
The study will consist of a s creening period (Days  -14 to 0) and a double-blind period (Day  1 
to Week  12). Subjects will attend a screening visit followed by visit s at Week s 0 (Day  1), 2, 4, 
8, and 12 (e nd of s tudy [ EOS ]) after randomization. An additional follow -up visit will be 
conducted at Week  26 to evaluate safety  and to perform a serum pregnancy test in women of 
childbearing potential ( WOCBP ). 
Page 211
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 33 Subjects having signed the informed consent form ( ICF) versions prior to the one introduced 
by this amendment need to re -consent to continue participating in the study after Week  12 
through Week 26. If a subject does not re -consent for further study participation after Week  12, 
then his/her study data up to Week 12 will be collected and the subject will be discontinued 
from the study.  
If a subject requires rescue t herapy after Week  12, then the same can be administered to the 
subject per investigator‚Äôs discretion until the additional safety follow -up visit at Week  26. If 
rituximab re -dosing becomes necessary at a time allowed by the local rituximab label , the same 
can be administered. Specifics of safety analysis of such subjects will be addressed in the 
statistical analysis plan ( SAP). Study procedures include physical examination , vital signs  
measurement , clinical laboratory assessment s, AEs, and concomitant medication . All subjects 
completing the study at Week  12 or  those discontinuing the study at any time will attend an  
EOS /early t ermination (ET) visit.   
The study endpoints are the incidence of anti -drug antibodies ( ADA) , including titer and 
neutralizing antibodies ( NAbs ), treatment -emergent adverse events ( TEAEs ), serious adverse 
events ( SAEs ), anaphylactic reactions, hypersensitivity reactions, and IRRs. The subject‚Äôs 
response to treatment will be assessed in accordance with usual clinical p ractice.  
Samples for the evaluation of ADA  will be obtained before the administration of study 
treatment on Day  1 and Day 15. Additional samples for detection of ADA will be collected at 
Weeks 4, 8, and 12 (EOS/ET visit ). Samples that are confirmed positive for ADA will be further 
tested for titer and NAb. Details are described in Section  6.2. 
A study scheme is provided in Figure 3-1. 
Page 212
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 34 Figure  3-1 Study Scheme  
 
Abbreviations:  ADA, anti -drug antibody; DRL _RI, biosimilar  rituximab ; N, total number of subjects; n, number 
of subjects in each treatment arm; RA, rheumatoid arthritis.  
Data until Week  12 will be analyzed and reported in the f inal Clinical Study Report (CSR) after 
all subjects complete Week  12 visit (EOS/ET). The subsequent follow -up data from Week  12 
to Week  26 will be reported as an addendum to the final CSR  and for the  data up to and 
including the Week 12 or ET visit.  
3.1.2 Rationale of Study Design 
This is a randomized, double -blind, parallel group, multicenter study designed to assess the 
immunogenicity of transitioning subjects with RA to DRL_RI from 
US-rituximab/EU -rituxi mab to continued treatment with US -rituximab/EU -rituximab . The 
study is part of the DRL_RI  development program to support DRL_RI  as a biosimilar. The 
comparators used in this study are US -licensed rituximab  (Rituxan) or EU -approved rituximab 
(MabThera). 
The parallel and double- blinded design study also allows for independent assessment of safety 
and immunogenicity of the DRL_RI arm  of the study relative to the control arms in these 
population to support registration. It also allows for the 2 control arms to be evaluated relative 
to each other. Randomization prevents the selection bias and insures against the accidental bias.  
Subject s who have received at least 1 full course comprising two 1000 mg infusions of either 
US-rituximab or EU -rituximab and are candidates for re- treatment with rituximab  will be 
Page 213
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 35 enrolled. DRL_RI will be administrated in combination with MTX as two 1000 mg infu sions 
on Day 1 and Day 15, which is consistent with the recommended dose for RA as described in 
the PI of Rituxan and the S mPC  for MabThera ( Rituxan PI 20 20, MabThera SmPC 20 20). 
Study endpoints are the incidence of ADA, including titer  and NAb ; TEAEs; and SAEs, 
anaphylactic reactions, hypersensitivity reactions, and IRRs. Samples for the evaluation of 
ADA  will be obtained before the administration of study treatment on Day 1 and Day 15, and 
at Weeks 4, 8, and 12 (EOS /ET) visits. Samples that are confirmed positive for ADA will be 
further tested for titer and NAb . An additional follow -up visit will be conducted at Week  26 to 
evaluate safety and to perform a serum pregnancy test in WOCBP.  
A validated enzyme -linked immunosorbent assay (ELISA) will be used to test ADA, titer  and 
NAb  by specialist laboratories ( sponsor designated laboratories) in this study.   
Along with immunogenicity sample, a time -matched blood sample ( approximately 5 mL ) will 
be collected for the estimation of rituximab concentration. The evaluation of the samples will 
be performed to interpret safety and/or immunogenicity data appropriately, if needed. 
3.1.3 Early Termination of the Study  
This study may be terminated prematurely at any time by Dr. Reddy‚Äôs Laboratories S.A. for 
medical, operational, or ethical reasons at individual or all study sites.  
If the study is prematurely terminated or discontinued, Dr. Reddy‚Äôs Laboratories  S.A./clinical 
research organization (CRO) will promptly notify the investigator s, institutions , and all 
competent regulatory authorities in writing outlining the reasons for the termination. The 
investigator or Dr. Reddy‚Äôs Laboratories  S.A./CRO will promptly inform the Independent 
Ethics Committee  (IEC) /Institutional Review Board  (IRB). After notification, the investigator  
must contact all participating subjects and the hospital pharmacies (if applicable) within a 
reasonable time period and inform them of the premature termination/discontinuation of the 
study. 
The clinical research associate will contact the investigators to schedule a close -out visit for 
all participating sites.  
As directed by Dr. Reddy‚Äôs Laboratories  S.A./CRO, all  unused study documents/ materials  (for 
e.g., study drugs, packing slips, stickers, etc.) shall be collected . All electronic case report 
Page 214
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 36 forms  (eCRF s) will be completed. All documents required for archiving at the site will be 
retained at the site itself. The study monitor will ensure that any outstanding data clarification 
issues and queries are resolved, and that all study records at the study site are complete . 
3.1.4 End of Study  
End of s tudy is defined as the time at which all subjects enrolled in the study have been 
followed for 10 weeks after treatment unless lost to follow -up or the subject  has died. The E OS 
is achieved at the last subject ‚Äôs Week  12 visit.  After EOS, a n additional follow -up visit will be 
conducted at  Week  26 to evaluate safety and to perform a serum pregnancy test in WOCBP. 
3.2 Study Conduct During the COVID- 19 Pandemic  
Coronavirus disease of 2019 ( COVID-19) is a viral illness caused by the novel coronavirus 
(also called the SARS -CoV-2) and has impacted most of the countries across the globe. It was 
declared as a global public health emergency by the World Health Organization on 
30 Jan  2020. This pandemic has im pacted the conduct of clinical trials in various ways.  
3.2.1 Benefit -Risk Assessment of Rituximab Treatment D uring the 
COVID- 19 Pandemic  
Rituximab is a known immunosuppressant drug  and immunosuppression/immunomodulation 
is the known mechanism of action for its v arious approved indications and clinical use, 
including its  use in RA.  
The current knowledge  about human immune response to COVID-19 is limited. It is also not 
precisely known whether patients on rituximab  are associated with a higher risk or with a 
higher severity of COVID- 19. However, given the general immunosuppressive nature, it 
cannot be ruled out entirely. M ethotrexate used concomitantly with rituximab in the treatment 
of RA  is also a known immunosuppress ant. It is known to increase the risk of opportunistic 
infections and has to be avoided during active infection. 
Rheumatoid arthritis is a chronic, symmetrical, inflammatory autoimmune disease that initially 
affects small joints, progressing to larger joints, and eventually affecting the skin, e yes, heart, 
kidneys, and lungs. At the advanced stage it leads to deformities and bone erosion, usually very painful for a patient ( Komatsu and Takayanagi  2012; Bullock et  al 2018). Moreover, there 
could be worsening of the disease , if the patient is deprived of the treatmen t. Hence, it is 
important to analyse the benefit -risk ratio  for a  particular patient on a case to case basis.
 
Page 215
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 37 Moreover, per recommendation by the A CR, in patients with moderate to high disease activity 
despite optimal conventional synthetic DMARDs, biologi cs may be started  (Mikuls TR  et al 
2020). In patients already on biologics who need a switch to rituximab, the same considerations 
would be expected to apply. 
Hence, based on the above considerations , the benefit of r ituximab t reatment outweigh the 
risks associated with  the current COVID -19 situation provided all steps are taken towards 
ensuring the subject interest and various contingency and safety measures are implemented 
towards the same. Various such measures have been taken to ensure safety and to minimize the 
risks for the subject s in compliance with the various recommendations and regulatory 
guidelines as well as disease management guidelines. 
3.2.2 Contingency Measures Taken During the COVID- 19 Pandemic 
Based upon the above mentioned considerations, the following measures have been 
implemented  in the study: 
1. COVID- 19 protective measures: Advice to the sites to implement g eneral hygienic 
measures for both ongoing subjects and any new subject  to educate on such protective 
and preventive measures . 
2. Assurance of subject safety by investigator before enrolment (by COVID -19 related 
screening  questionnaire) . 
3. Measures to be taken if i nvestigator suspect COVID -19-related symptoms or if a 
subject is found positive to COVID-19. 
4. In order to protect subject ‚Äôs safety and welfare, it is also recommended that site contacts 
subjects periodically ( preferably on Day 7, 14 ; Weeks 6, 10, 14, 18, and 22) via 
telephone to inquire about his/her overall well -being, to seek informatio n on alarm 
symptoms (fever, cough, breathlessness , COVID-19- related skin lesion , etc) of 
COVID- 19 infection, information on subject ‚Äôs contact with any COVID-19-positive 
patient, and to guide the subjec t to take appropriate medical care.  
If a study subject has an event suspected to be COVID -19 related , the investigator will 
have to decide on performing COVID -19 testing per local health authority or study site 
guidance. 
Page 216
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 38 Any new AE or change in the intensity of ongoing AE(s) with special focus on 
symptoms rela ted to COVID- 19, new medication(s)  taken by the subject  since his/her 
last visit , or any change in dos e/frequency of medication (s), which is received, will be 
also documented in the source documents and eCRF.  
5. Any event of COVID-19 is to be considered as an ‚ÄúEvent of Special Interest‚Äù and all 
relevant detailed information will be collected, such as diagnosis, management and 
outcome. All events related to or linked to COVID -19 and meeting SAE criteria must 
be reported to Pharmacovigilance within 24  hours of the investigator‚Äôs knowledge 
of the event by facsimile or other appropriate method. 
Moreover, due to current COVID -19 pandemic situation, remote source data 
verification may be performed per local regulations. All details of remote monitoring 
will be captured in the monitoring plan, if required.  
A detailed information about the type of data to be collected, handing of missing data 
or assessment/procedure will be captured in the eCRF filling guidelines/data 
management plan  if required. Listings/summaries of all s ubjects affected due to 
COVID-19, including protocol deviations, additional safety contingency measures will 
be generated based on the available data  if required . Corresponding detail s will be 
mentioned in the SAP.  
If COVID-19 wanes off, the sponsor may  not collect  COVID-19- specific data (as 
mentioned above) and may not follow -up with the subject for COVID-19- related 
information . In such a case , the CRO and site will be notified for further action.   
Page 217
CI
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 39 4 Subject Selection and Withdrawal Criteria 
4.1 Selection of Study Population 
Approximately 140 subjects will be enrolled at approximately 50 sites in up to 7 countries . 
Subjects will be assigned to study treatment only if they meet all of the inclusion criteria and 
none of the exclusion criteria.  
Deviations from the inclusion and exclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability, or subject safety. Therefore, adherence to the criter ia as specified in the protocol is essential . 
4.1.1 Inclusion Criteria  
A subject will be eligible for enrolment in the study if he/she meets all of the following criteria:  
1. Male or female subjects aged 18 years or older who have provided valid written 
informed consent. 
2. Subjects with a diagnosis of active RA who are eligible for the subsequent treatment course with US-rituximab  or EU-rituximab  according to the clinical judgment of the 
investigator. 
3. Documented evidence that subject has received at least 1 full course comprising two 
1000 mg infusions of either US -rituximab  at least 16  weeks prior to the randomization 
visit or EU -rituximab  at least 24  weeks prior to the day of randomization visit.  
Note:  Subjects are only eligible if they have received the prior US or EU -rituximab 
course within the 15 months prior to the date of randomization.  
4. Subjects receiving a stable dose of weekly MTX  for at least 4  weeks prior to 
randomization (between 7.5 mg and 25 mg) and folic acid (at least 5  mg per week).  
4.1.2 Exclusion Criteria  
Subjects meeting any of the following criteria must not be enrolled in the study : 
1. Subjects with RA  in functional Class IV  (Table 14 -2). 
Page 218
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 40 2. Subjects with human immunodeficiency virus  (positive HIV1Ab or HIV2Ab) , 
hepatitis  B virus and/or hepatitis  C virus infection, including those with positive results 
in the viral disease scree ning ( Section  6.1.1). 
3. Subjects with active tuberculosis ( TB). Subjects with evidence of latent TB or a history 
of TB must have completed treatment or have initiated treatment for at least 1  month 
before the first dose of study treatment (Day  1). TB testing is required only if it is 
required by local regulations or practice. 
4. Active systemic infection.  
5. Severely immunocompromis ed. 
6. History of hypersensitivity to either US -rituximab  or EU-rituximab  or any of its 
excipients.  
7. Any serious illness or uncontrolled medical condition, including, but not limited to , 
severe infections, significant hepatic or renal disease, uncontrolled hyperte nsion 
despite treatment (defined as blood pressure  [BP]  ‚â•160/95 mmHg), congestive heart 
failure (New York Heart Association [NYHA] C lass III or IV), or other severe 
uncontrolled cardiac disease or uncontrolled diabetes with immediate risk of acute 
complica tions.  
8. Any condition that in the opinion of the investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for subjects.  
9. Requir es treatment with any biological medicinal product during the study other than 
the stu dy treatment. 
10. Previous treatment with B -cell modulating or cell-depleting biologic therapy , except 
US-rituximab  or EU -rituximab . 
11. Prior participation in this clinical trial or prior participation in any clinical trial with any monoclonal antibody within 12 months of screening or prior participation in any 
clinical trial within 3  months of screening or within 5 half -lives of the investigational 
drug or until the expected PD effect has returned to baseline, whichever is longer. 
12. Treatment with other b iologic DMARDs, or Janus kinase ( JAK) inhibitors 
administered within 12  weeks before the first dose of rituximab of the prior treatment 
course onwards till the date of randomization.  
Page 219
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 41 13. Subjects with the following laboratory abnormalities: 
‚Ä¢ Subjects with scree ning total white blood cell count <3000/ ŒºL, 
platelets  <100,000/ ŒºL, neutrophils <1500/ ŒºL, or hemoglobin <8.5 g/dL. 
‚Ä¢ Abnormal liver function tests such as aspartate aminotransferase, alanine 
aminotransferase, or alkaline phosphatase >2 √ó upper limit of normal  (ULN) . A 
single parameter >2  √ó ULN can be re -checked as soon as possible, at least prior to 
randomization, if required as per the investigator‚Äôs discretion . 
‚Ä¢ Creatinine clearance ( Cockcroft & Gault formula) of less than 50  mL/min.  
14. History of vaccination with live vaccines within 4  weeks of the first dose of study 
treatment (Day  1) or known to require live vaccines during the study. 
15. Lactating or pregnant female.  
16. Wom en of childbearing potential who do not consent to use highly effective methods 
of birth control during treatment and for at least 12 months after the last administration 
of study treatment. 
Note: Per the Clinical Trial Facilitation Group ( CTFG) guidelines 2014, a wom an is 
considered of childbearing potential  if fertile, following men arche until becoming 
postmenopausal (i.e., no menses for 12 months without an alternative medical cause) 
unless permanently sterile through hysterectomy , bilateral salpingectomy , and bilateral 
oophorectomy). Highly effective birth control measures per CT FG guidelines 2014 
include the following: 
‚Ä¢ combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation  - oral, intravaginal, and transdermal 
‚Ä¢ progestogen- only hormonal contraception associated with inhibition of 
ovulation - oral, injectable, and implantable  
‚Ä¢ intrauterine device  
‚Ä¢ intrauterine hormone -releasing system  
‚Ä¢ bilateral tubal occlusion  
‚Ä¢ vasectomised partne r 
‚Ä¢ sexual abstinence 
Page 220
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 42 Site should advi se subjects to use any of the methods listed above, or per the 
country/site -specific requirement s. 
17. Sexually active male subjects unless permanently sterile by bilateral orchidectomy, 
who do not agree to use 1 of the highly effective methods of birth control listed in  
Exclusion Criterion #16 during treatment and for at least 12 months after the last 
administration of study treatment.  
18. Subjects with serum IgG <LLN. 
4.2 Withdrawal of Subjects From  Study Treatment and/or  the Study  
The duration of the study is defined for each subject as the date when signed written ICF is 
provided through the EOS visit  on Week  12. A n additional follow -up visit will be conducted 
at Week  26 to evaluate safety and  to perform a serum pregnancy test in WOCBP. Subjects 
having signed the ICF versions prior to the one introduced by this amendment  need to 
re-consent t o continue participating in the study after Week  12 through Week 26. If a subject 
does not re- consent for further study participation after Week  12, then his/her study data up to 
Week 12 will be collected and the subject will be discontinued from the study. 
4.2.1 Reasons for Withdrawal /Discontinuation  
Subjects may withdraw from the study at any time and for any reason without prejudice to their  
future medical care by the investigator or at the study site. Every effort should be made to keep 
subjects in the study. The reasons for subjects not completing the study will be recorded. A 
subject may be withdrawn from the study for any of the following reasons: 
1. The subject does not meet the protoc ol inclusion or exclusion criteria before the last 
scheduled dose of study treatment is administered. If the first dose of study drug was 
already administered, the subject should not receive the second dose of study drug, but study follow-up should be completed. 
2. The subject is n oncompliant with the protocol  that in the investigator‚Äôs opinion requires 
withdrawal from the study . 
3. The subject has a serious or intolerable  AE(s) that in the investigator‚Äôs opinion requires 
withdrawal from the study . 
4. The subjec t has symptoms or an intercurrent illness not consistent with the protocol 
requirements or  that justify withdrawal. 
Page 221
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 43 5. The subject is lost to follow-up. 
6. Other  reasons (e.g., pregnancy, development of contraindications of use of study 
treatment). 
7. The subject w ithdraws consent from study participation or from further treatment, or 
the investigator or sponsor decide s to discontinue the subject‚Äôs participation for  a 
specific safety reason in the study , or the subject does not re -consent to continue 
participation in the study after Week  12. 
Note : If a subject withdraws consent for further study treatment, but not for study participation, 
the subject  can continue further visits and data can continue to be  collected  until Week  26. 
However, if a subject withdraws consent for further participation in the study there will be no 
further data collection and th e subject will be discontinued from the study . If a subject  having 
signed the ICF versions prior to the one introduced by this amendment  does not re -consent for 
further study participation after Week  12, then his/her study data up to Week 12 will be 
collected and the subject will be discontinued from the study. If Dr. Reddy‚Äôs Laboratories S.A. 
terminates the  study all subjects will be withdrawn .  
Upon occurrence of a serious or intolerable AE, the investigator will confer with the sponsor  
before withdrawing the subject. If a subject is discontinued because of an AE, the event will be followed until it is reso lved, or it is deemed in the opinion of the investigator that the AE is 
stabilized and further follow -up is not required. Any subject may withdraw his or her consent 
at any time.  
4.2.2 Handling of Withdrawals  
During the study, the s ubjects can independently withdraw from study treatment and/or study 
participation at any time . Also, the subjects may be withdrawn from the study at any time at 
the discretion of the investigator or sponsor for safety, behavioral, or administrative reasons, 
or the in ability of the subject to comply with the protocol required schedule of study visits or 
procedures at a given study sit e. 
The decision to withdraw consent and discontinue participation in the study will not prejudice 
the subject‚Äôs future medical treatment in any way. If a subject does not return for a scheduled 
visit, every effort will be made to contact the subject. All attempts to contact the subject and 
information received during contact attempts ( 3 attempts with minimum 2 different modes to 
follow -up/contact) must be documented in the subject‚Äôs medical record. In any circumstance, 
Page 222
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 44 every effort will be made to document subject outcome, if possible. The investigator  should 
inquire about the reason for withdrawal and request the subject to return for the E OS/ET 
(Week  12) visit, if applicable, and follow -up with the subject regarding any unresolved AEs.  
An additional follow -up visit will be conducted at Week 26 to evaluate safety and to perform 
a serum pregnancy test in WOCBP.  The investigator or sub-investi gator or designee will be 
responsible for reporting subject withdrawal to Dr. Reddy‚Äôs Laboratories  S.A./CRO. Subjects 
withdrawn from the study cannot be re -enrolled at a later time, regardless of the reason for 
withdrawal.  The reason of withdrawal should be provided in the eCRF.  
If the subject withdraws consent for further treatment, but consents to study participation, data 
will continue to be collected  until Week  26.  
Subjects having signed the ICF versions prior to the one introduced by this amendment  need 
to re-consent to continue participating in the study after Week  12 through Week 26. If a subject 
does not re- consent for further study participation after Week  12, then his/her study data up to 
Week  12 will be collected and the subject will be discontinued from the study.  
If a subject withdraws consent from study participation after Week  12 but before the additional 
follow -up visit at Week  26, he/she will be require d to undergo the Week 26 assessments on the 
day of study discontinuation. If a subject consents to undertake additional and optional study 
procedures/assessments but withdraws consent for doing so at a later visit, he/she will be retained in the study for the routine study procedures/assessments. 
If a sub ject withdraws from the study and also withdraws consent for disclosure of future 
information, the subject will undergo ET visit assessments . Dr. Reddy‚Äôs Laboratories  
S.A./CRO may retain and continue to use any data collected before such withdrawal of consent.  
4.2.3 Replacements 
Subjects who withdraw or discontinue after randomization are not to be replaced. 
Page 223
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 45 5 Study Treatments 
5.1 Method of Assigning Subjects to Treatment Arms  
After writte n informed consent  is obtained from an eligible subject , a unique subject 
identification  number will be assigned to this subject at screening visit.  Subjects will be 
identified during the whole study only by their assigned subject identification number.  
Subjects will be randomly assigned at the baseline/ randomization v isit ( Day 1) to receive 
DRL_RI or US -rituximab  or EU-rituximab using a 1:1 allocation ratio. A n IW RS will be used 
to administer the randomization schedule. Biostatistics will generate the randomization 
schedule using statistical analysis system ( SAS) software Version  9.4 or later (SAS Institute 
Inc, Cary, North Carolina , US) for I WRS, which will link s equential subject randomization 
numbers to treatment codes. The randomization schedule will be stratified by region (US/EU) . 
It will also use an appropriate block size, which will not be revealed.   
Dispensing of study treatment will be coordinated by IWRS on Day 1 and Day 15. The system 
will assign a kit number corresponding to the randomization arm by region (US/EU).  
Randomization plan document will be prepared before the generation of randomization 
schedule. The randomization code will be computer -generat ed and kept by a statistician 
independent from the project team.  
This randomization number identifies which treatment will be allocated to each subject. The 
subject identification number of s ubjects who withdraw or discontinue before or after the 
randomization will not be re -used. 
5.2 Treatments Administered  
This is a randomized, double-blind, and parallel group clinical study. 
Following signing of ICF , subjects will be registered into the study to receive a unique subject 
identification number. Random ization will be performed using an IWRS. Subjects will be 
randomized in a 1:1 ratio to 1 of the 2 study treatment arms  as follows : 
‚Ä¢ Arm A:  DRL_RI ( proposed rituximab biosimilar)  
‚Ä¢ Arm B:  US-rituximab  or EU -rituximab  
Page 224
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 46 The study treatments  DRL_RI or US -rituximab /EU-rituximab will be administered as two  
1000 mg IV infusions separated by 2 weeks ( Section  5.2.3 ). Subjects will be pre -medicated 
before each infusion ( Section  5.2.2 ). 
5.2.1 Study Treatment Infusion Preparation  
Study treatment (DRL_RI or US -rituximab/EU -rituximab) solutions for infusion will be 
prepared by unblinded pharmacist designated as site team member in this study. Study 
treatment will be administered by IV infusion. It  should not  be administered as an IV push or 
bolus. 
Pharmacists should use aseptic techniques appropriate to parenteral administration projects. 
Study treatment vials and prepared solutions should be inspected visually for particulate matter 
and discoloration prior to administration. The necessary amount of study treatment  will be 
withdrawn and diluted to a final concentration of 1 to 4 mg/mL in an infusion bag containing 
either 0.9% sodium chloride, United States Pharmacopeia, or 5% dextrose Injection , United 
States Pharmacopeia . The infusion bag should be gently inverted to mix the solution. Do not 
use vials if particulates or discoloration are present. Further information can be obtained in the 
pharmacy manual. 
5.2.2 Pre-medication for Study Treatment Infusions  
Pre-medica tion consisting of an antipyretic and an antihistamine (e .g., paracetamol 
[acetaminophen] and diphenhydramine) should always be administered before each infusion 
of rituximab.  
All subjects should also receive pre -medication with 100  mg IV methylprednisolon e or its 
equivalent to be completed at least 30 minutes prior to rituximab infusions to decrease the 
incidence and severity of acute IRRs . 
Acute IRRs are most often observed during the first infusion of rituximab. Any reduction in 
use of pre -medications during subsequent infusion must be in compliance with local labelling 
and regulation(s) . 
5.2.3 Study Treatment Administration  
Study treatments  (DRL_RI or US -rituximab/EU -rituximab) will be administered by IV 
infusion using the escalating infusion rate described in the Health Authority -approved product 
Page 225
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 47 labels for US-rituximab/EU -rituximab. The infusion rate must be well controlled to reduce the 
incidence of serious IRRs.  
Only qualified personnel who are familiar with procedures that minimi ze undue exposure to 
them and to the environment should undertake the preparation, handling, and safe disposal of 
biological agents. 
Study treatment infusions should be administered under close medical supervision and in an 
environment where full resuscitation facilities are immediately available. Vital signs will be 
monitored every 30 minutes (¬± 5 minutes) during the course of the treatment administration or 
more frequently as necessary.  
The study treatments will be administered as two  1000 mg IV infusions on Day 1 and Day 15. 
Below instructions should be followed in consolidation with the local product labelling if it 
differs from these instructions.  
‚Ä¢ First infusion (Day  1): Initiate infusion at a rate of 50  mg/hour. In the absence of 
infusion toxicity, increase infusion rate by 50 mg/hour increments at 30- minute 
intervals , to a maximum of 400 mg/hour. 
‚Ä¢ Second i nfusion (Day  15): Initiate infusion at a rate of 100  mg/hour. In the absence of 
infusion toxicity, increase rate by 100  mg/hour increments at 30- minute intervals, to a 
maxim um of 400 mg/hour. 
‚Ä¢ Subjects should be closely monitored post- dose for at least 1  hour for the onset of IRRs . 
Subjects who develop evidence of severe reactions, especially severe dyspnea, bronchospasm, or hypoxia should have the infusion interrupted immedia tely. In all 
subjects, the infusion should not be restarted until complete resolution of all symptoms and normalization of laboratory values  is achieved . At this time, the infusion can be 
initially resumed at not more than one -half the previous rate. If th e same severe 
reactions occur for a second time, the decision to stop the treatment should be seriously 
considered on a case -by-case basis.  
‚Ä¢ Mild to moderate IRRs  usually respond to a reduction in the rate of infusion. The 
infusion rate may be increased upon improvement of symptoms. 
Page 226
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 48 5.3 Identity of Investigational Product  
Proposed r ituximab biosimilar ( DRL_RI ) or US -rituximab/EU -rituximab will be provided  as 
study treatment  to the participating sites.  
DRL_RI and US -rituximab/EU -rituximab will be supplied as sterile, preservative -free, 
non-pyrogenic, single -use vials. Each 100 mg vial will contain 100 mg unit dose of DRL_RI 
or US-rituximab/EU -rituximab in 10  mL single -use vial or each 500 mg vial will either contain  
500 mg unit dose of DRL_RI or US -rituximab/EU -rituximab in 50  mL single- use vial.  
5.4 Management of Clinical Supplies  
5.4.1 Packaging 
Rituximab concentrate for solution for infusion will be packaged in a carton or kit. Each carton 
or kit will have 2 vials of 500 mg vials to achieve 1000 mg of single dose (on D ay 1 and 
respectively on D ay 15) OR 10 vials of 100 mg to achieve 1000 mg of single dose (on D ay 1 
and respectively on D ay 15). Each carton will be packaged with a tamper -resistant seal. The 
sponsor must be notified of any study medication in which the tamper -resistant seal has been 
broken and this medication should not be used. Further details will be provided in the pharmacy 
manual. 
5.4.2 Labelling  
Medication labels will comply with the legal requirements of each country and be printed in 
local language, if required. They will supply no information about the subjects. 
5.4.3 Storage  
DRL_RI and US -rituximab/EU -rituximab 100 mg/10 mL single -use vials and 500 mg/50 mL 
single- use vials should be stored  at 2¬∞C to 8¬∞C (36¬∞F to 46¬∞F). Do not use beyond expiration 
date stamped on carton. DRL_RI and US -rituximab/EU -rituximab  vials should be protected 
from direct sunlight. Do not freeze or shake.  
From a microbiological point of view, the prepared DRL_RI  and US -rituximab/EU -rituximab  
solutions for infusion should be used immediately. Further details regarding preparation and 
storage of study treatments will be provided in pharmacy manual.  
Page 227
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 49 The investigator, or an approved representative (e .g., pharmacist),  will ensure that all study 
treatment is stored in a secured (locked) area with restricted access, and in accordance with 
applicable regulatory requirements.  
Study treatment should be stored in accordance with the drug label. Investigators and site staff 
should ensure that thermometers are working correctly,  and the drug is being stored as required 
for proper storage of study treatment s. More details will be captured in pharmacy manual. Any 
temperature excursions should be reported to the sponsor or sponsor designate. 
Deviations from the storage requirements, including any actions taken, must be documented 
and reported to the sponsor or sponsor designate. Once a deviation is identified, the study 
treatment must be quarantined and not used until the sponsor provides documentation of 
permission to use the study treatment . 
5.4.4 Study Treatment Accountability  
Records will be maintained of the delivery of study treatment  to the study site s, the inventory 
at the study sites, the use of each subject , and the return to the sponsor.  
These records shall include dates, quantities, batch numbers, expiry dates , and the unique code 
numbers assigned to the study medication and to the study subjects. 
The investigator shall be re sponsible for ensuring that the records adequately document that 
the subjects were provided the study treatment specified by the IWRS and that all study 
medication received from the sponsor is reconciled. 
5.5 Overdose Management 
An overdose is any dose of study treatment given to a subject or taken by a subject that exceeds 
the dose described in the protocol. Every overdose must be reported to the s ponsor or sponsor‚Äôs 
designated safety services within 24  hours of awareness, irrespective of whether the overdose 
was associated with an AE/SAE. Overdoses without signs or symptoms do not need to be 
recorded as AEs; in case of any AEs associated with an overdose, these should be reported in 
the relevant AE/SAE sections of the eCRF.  
Page 228
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 50 5.5.1 Medication Errors  
Medication errors may result in this study from the administration or consumption of the wrong 
drug, by the wrong subject, at the wrong time, or at the wrong dosage strength. In the event of 
medication dosing error, the sponsor should be notified immediately. 
Medication err ors are reportable irrespective of the presence of an associated AE/SAE, 
including: 
‚Ä¢ Medication errors involving subject exposure to the study treatment . 
‚Ä¢ Potential medication errors or uses outside of what is foreseen in the protocol that do or do 
not invol ve the participating subject.  
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error should be captured on the medication error version of the AE 
page and, if applicable, any associated AEs are captured on an AE e CRF page.  
5.6 Transmission of Infectious Agents 
All subjects will be provided with patient alert card with each infusion. The alert card contains important safety information for subjects regarding potential increased risk of infections, 
including progressive multifocal leukoencephalopathy. 
5.7 Blinding  
A double -blind design is employed so that both the investigators and the subjects will be 
unaware of the treatment assignment during the whole study. Moreover, study center staff involved in study treatment  administration and study endpoints assessments, CRO personnel, 
and the sponsor team including study statistician will be blinded to the treatment received. The 
clinical laboratories analyzing the blood/plasma samples and the concentration/incidence of 
anti-rituximab antibodies will also be blinded to the treatment assignment. A team from the 
CRO, independent to the clinical monitoring group, shall be responsible for maintaining drug 
accountability logs. An unblinded study coordinat or or pharmacist at each site will be 
responsible for maintaining drug accountability as well as for dispensing. The final CSR  will 
include all end points , after all subjects complete the Week 12 (EOS/ET) visit  and the database 
up to the Week 12 (EOS/ET visit) has been locked. The study will be  unblinded after the 
database up to the EOS/ET visit has been locked.  The subsequent follow -up data from Week 12 
Page 229
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 51 to 26 will be reported as an addendum to the final CSR and for the data up to and including the 
Week 12 or ET visit.  
5.7.1 Breaking the Blind 
A subject‚Äôs treatment assignment will not be broken until the EOS  unless medical treatment of 
the subject depends on knowing the study treatment the subject received. In the event  that the 
blind needs to be broken because of a medical emergency, the investigator may unblind an 
individual subject‚Äôs treatment allocation.  
The study site investigator and appropriate project team members will be authoriz ed to access 
the emergency unblinding functionality within the IWRS. The system will require the user to enter an authori zation key number to complete the emergency unblinding transaction. The 
exact description of the treatment assigned to the individual subject then will be accessible. Emergency unblinding can thus be made for any subject without affecting the double -blind 
nature of the study. Subject treatment information may only be accessed in the event of an emergency and out of necessity to know the identity of the allocated study tr eatment  in order 
to institute appropriate therapeutic management. Should a situation arise where unblinding is urgently required (i .e., knowledge of treatment code is required to adequately manage a 
life-threatening situation), the investigator at that study site may perform immediate unblinding 
through the IWRS. If time allows, the investigator should contact the m edical monitor prior to 
unblinding the individual subject to discuss the rationale for emergency unblinding.  
In the event that emergency unblinding is performed, the investigator can view and must print 
the blinded confirmation document from IWRS. The investigator must record on the 
confirmation document printout the reason for the emergency unblinding and sign t he 
document. The confirmation document must then be kept in a safe place until Week  26. Once 
a randomization code has been broken for a subject, he/she must be withdrawn from the study. 
The investigator must inform the medical monitor /designee in writing within 24  hours. 
5.8 Treatment Compliance 
Study treatment  will be administered under the supervision of the investigator and site 
personnel. Compliance will be monitored by study personnel at the site by using the source 
documents and the eCRF. The  site study unblinded pharmacist/authorized designee is 
responsible for drug preparation, the maintenance of accurate and complete dispensing and 
Page 230
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 52 accountability forms showing the receipt and dispensation of the study treatment . The 
pharmacist will also be responsible for performing accountability and reconciliation of the 
study treatments. 
5.9 Prior and Concomitant Therapy  
Medication s that are  considered necessary for the subject‚Äôs safety and well -being may be given 
during the course of the study at the discretion of the investigator and must be recorded in the appropriate sections of the eCRF.  
All medications taken by a subject within 1 month prior to the screening visit are regarded as 
prior medication  and must be documented as such in the e CRF.  
All medication s still being taken by a subject at randomization and which continue to be taken 
during the study and medications started during the study are regarded as concomitant 
medication  and must be documented as such in the e CRF.   
5.9.1 Background Medication  
A stable dose of weekly MTX (7.5 mg to 25 mg) and folic acid (at least 5  mg per week) that 
the subject is receiving are considered as background medications. Subjects have to be on a stable dose of weekly MTX (between 7.5  mg and 25 mg) for at least 4  weeks prior to 
randomization and during the study and folic acid (at least 5 mg per week). 
Note: MTX and folic acid should be used in accordance with the guidelines specified in the 
local label (e.g. , SmPC in the EU , US PI for the US ). Folinic acid at the same dose of folic 
acid, can be given in place of folic acid if it is allowed by the local label. Subject should take 
the same folate supplementation throughout the duration of the study . 
5.9.2 Other Concomitant Medication  
Low- dose corticosteroids (‚â§10  mg/d ay prednisone equivalent) and non-steroidal  
anti-inflammatory drugs  as needed are permitted concomitant medications for RA  during this 
study. 
Concomitant administration of any other experimental drug , biological medicinal products, 
B-cell modulating or cell -depleting biologic therapy, JAK inhibitors, anti-rheumatic drugs 
including DMARDs  other than MTX (along with folic acid), tofacitinib, glucocorticoids used 
Page 231
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 53 as pre -medication  other than methylprednisolone or its equivalent, or immunotherapy is 
prohibited during study participation. 
Page 232
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 54 6 Study Assessments and Procedures 
Before performing any study procedures, all potential subjects will sign an ICF. Subjects will 
have the opportunity to have any questions answered before signing the ICF. The investiga tor 
must address all questions raised by the subject. The investigator or designee will also sign the ICF. 
6.1 Schedule of Assessments 
An overview of the protocol visits and procedures is provided in Table  14-1. 
The investigator may plan unscheduled visits in addition to those listed on the schedule of 
activities, in order to conduct evaluations or assessments required to protect the well -being of 
the subject.  If any unscheduled visits happen at any time during the study, visit 
details/appropriate data including the reason will be collected  in the eCRF.  
6.1.1 Screening Period  (Days - 14 to 0)  
Subjects will undergo a screening visit , within 14 days prior to the planned first day of study 
treatment. During the screening visit, subjects will be screened at the study site to confirm their 
eligibility for participation in the study. The investigator or sub -investigator will discuss with 
each subject the nature of the study,  its requirements, and its restrictions. Written and signed 
ICF must be obtained from each subject prior to the conduct of any protocol -specific 
procedures. 
Screening procedures and assessments will be as follows:  
The proposed chronological order of the assessments below should be followed. 
1. Obtain written informed consent  from the subject in accordance with local regulations.  
2. Register screening of the subject.  
3. Review subject eligibility (inclusion and exclusion criteria). Any questions regarding 
subject eligibility can be addressed to the medical monitor . 
Page 233
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 55 4. Document medical and surgical history  (includes full history of RA and other rheumatic 
diseases, including t heir related procedures, all ongoing conditions at the time of 
screening, all major surgical procedures [i .e., those involving opening of cavities or 
epidural or general anesthesia] with their reason , and any past event or procedure 
considered relevant by the investigator as well as any minor event occurring in the 
month prior to  screening).  
5. Document subject demographics. 
6. Clinical assessments will include the following: physical examination (including height 
and weight) , vital signs  measurement ( seated BP, heart rate, respiration rate, and oral 
body temperature).  
7. Serum pregnancy test ( beta- human chorionic gonadotropin [Œ≤-hCG] ) to be performed 
for WOCBP . Female subjects with documented history of hystere ctomy, bilateral 
salpingectomy, bilateral oophorectomy, medically confirmed ovarian failure, or 
screening follicle -stimulating hormone (FSH) test demonstrating postmenopausal status 
are exempt ed from pregnancy testing.  
8. Clinical laboratory assessment s: a blood sample will be taken for hematology and 
biochemistry ; urinalysis will also be performed.  
9. Tuberculosis screening (if required by local regulation or practice).  
10. Viral disease screening: hepatitis B surface antigen (HBsAg), hepatitis B core antibody 
(HBcAb ), hepatitis C virus ( HCV), and human immunodeficiency virus (HIV).  
Note: For HBcAb , site is requested to perform HBcAb  IgG and HBcAb IgM . If any of 
these 2 results is  positive, then the subject will be considered as screen failure. 
11. Twelve -lead electrocardiogram ( ECG ). 
12. Assess AE(s).  
13. Prior and ongoing medications. 
14. Serum Immunoglobulin (IgG  and IgM) 
Subjects who do not meet the criteria for participation in this study (screen failure) may be 
rescreened at the investigator‚Äôs discretion, following discussion with the s ponsor designee 
medical monitor . Subjects not included in the study due to latent TB (in the locations where 
Page 234
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 56 TB screening is required) will also require rescreening after appropriate treatment has be en 
administered per local guidance. 
6.1.2 Treatment Period (2 W eeks)  
Subjects will attend study visits at Week  0 (Day  1) + 1 day and Week 2 (Day  15) + 1 day.  
Samples for the evaluation of ADA, including titer and NAb (immunogenicity assessments) , 
will be obtained before the administration of study treatment on Day 1 and Day  15.  
In the description of evaluations below: 
Study Day 1 (Week 0, Baseline Visit)  
Eligible subjects will return to the study site for the baseline (Week  0, Day 1) visit. Subjec ts 
must satisfy all inclusion/exclusion criteria in order to be eligible for randomization.  
Baseline procedures and assessments should be conducted in chronological order as follows:  
1. Re-review subject eligibility (inclusion and exclusion) criteria to ensure that the subject 
continues to be eligible for inclusion into the study. Any questions regarding subject 
eligibility can be addressed to the medical monitor . 
2. Clinical assessments will include the following: physical examination , vital signs 
measurement (seated BP , heart rate, respiration rate , and oral body temperature).  
3. Urine pregnancy test for WOCBP . 
4. Clinical laboratory assessments: a blood sample will be taken for hematology and 
biochemistry ; urinalysis will also be performed  (see Section 6.3.4 for the list of clinical 
laboratory assessments ).  
Note: Viral disease screening (HBsAg,  HBcAb , HCV , HIV) , and serum IgG and IgM 
and TB screening  will not be repeated on Day 1 of the study. Clinical laboratory 
assessments scheduled on Day  1 can be performed 1 day prior to dosing. 
Note: For HBcAb, site is requested to perform HBcAb IgG and HBcAb IgM. If any of 
these 2 results is  positive, then the subject will be considered as screen failure. 
5. Randomize the subject in accordance with the IWRS.  
Page 235
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 57 6. Collect plasma samples for immunogenicity assessments prior to administration of 
study treatment. 
7. Collect a time -matched blood sample (approximately 5  mL) for the estimation of 
rituximab concentration.   
8. Study treatment administration and observation for at least an hour post infusion. 
9. Assess AE(s).  
10. Record concomitant medication (s). 
Study Day  15 (Week 2 + 1 Day) 
The procedures and assessments are as follows:  
1. Clinical assessments will include the following: p hysical examination , vital signs 
measurement (seated BP , heart rate, respiration rate , and oral body temperature).  
2. Urine pregnancy test for WOCBP . 
3. Clinical laboratory assessments: a blood sample will be taken for hematology and 
biochemistry ; urinalysis will also be performed.  
4. Collect plasma  samples for immunogenicity assessments prior to administration of 
study treatment. 
5. Collect a time -matched blood sample (approximately 5  mL) for the estimation of 
rituximab concentration.  
6. Study treatment administration  and observation for at least an hour post infusion. 
7. Assess AE(s).  
8. Review concomitant medications.  
Page 236
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 58 6.1.3 Follow -Up Period (10 W eeks)  
Week  4 ¬± 7 Days 
The procedures and assessments for Week  4 ¬± 7 days are as follows:  
1. Clinical assessments will include the following: physical examination  (including 
weight), vital signs measurement (seated BP , heart rate, respiration rate , and oral body 
temperature).  
2. Urine pregnancy test for WOCBP . 
3. Clinical laboratory assessments: a blood sample will be taken for hematology and 
biochemistry ; urinalysis will also be performed.  
4. Collect plasma s amples for immunogenicity assessments.  
5. Collect a time -matched blood sample (approximately 5 mL ) for the estimation of 
rituximab concentration . 
6. Assess AE(s).  
7. Review concomitant medications.  
Week  8 ¬± 7 Days 
The procedures and assessments for Week  8 ¬± 7 days are as follows:  
1. Clinical assessments will include the following: physical examination  (including 
weight), vital signs measurement (seated BP , heart rate, respiration rate , and oral body 
temperature).  
2. Urine pregnancy test for WOCBP . 
3. Clinical laboratory assessments: a blood sample will be taken for hematology and 
biochemistry ; urinalysis will also be performed.  
4. Collect plasma s amples for immunogenicity assessments.  
5. Collect a time -matched blood sample (approximately 5 mL ) for the estimation of 
rituximab concentration . 
6. Assess AE(s).  
Page 237
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 59 7. Review concomitant medications.  
6.1.4 End of Study/Early Termination Visit (Week 12 ¬± 7 Days) 
Subjects who complete the study or discontinue from the study at any time  will attend an 
EOS /ET visit .  
The EOS/ET assessments are as follows:  
1. Clinical assessments will include the following: physical examination  (including 
weight),  vital signs measurement (seated BP, heart rate, respiration rate , and oral body 
temperature).  
2. Serum pregnancy test ( Œ≤-hCG) for WOCBP . Female subjects with documented history 
of hysterectomy, bilateral salpingectomy, bilateral oophorectomy, medically confirmed 
ovarian failure, or screening FSH test demonstrating postmenopausal status are 
exempted from pregnancy testing. 
3. Clinical laborat ory assessments: a blood sample will be taken for hematology and 
biochemistry ; urinalysis will also be performed.  
4. Twelve -lead ECG.  
5. Collect plasma  samples for immunogenicity assessments. 
6. Collect a time -matched blood sample (approximately 5 mL ) for the estimation of 
rituximab concentration . 
7. Assess AE (s). 
8. Review concomitant medication(s). 
6.1.5 Additional Follow -Up Visit ( Week  26) 
The following assessments will be performed at Week  26: 
1. Clinical assessments will include the following: physical examination  (including 
weight),  vital signs measurement (seated BP, heart rate, respiration rate, and oral body 
temperature).  
Page 238
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 60 2. Serum  pregnancy test for WOCBP.  Female subjects with documented history of 
hysterectomy, bilateral salpingectomy, bilateral oophorectomy, medically confirmed 
ovarian failure, or screening FSH test demonstrating postmenopausal status are 
exempted from pregnancy testing. 
3. Clinical laboratory assessments: a blood sample will be taken for hematology  
(especially  absolute neutrophil c ount) and biochemistry; urinalysis will also be 
performed. 
4. Twelve -lead ECG.  
5. Assess AE(s) . 
6. Review concomitant medications . 
6.2 Immunogenicity Endpoint  
The immunogenicity  endpoint is the incidence of ADA, including titer and NAb.  
6.2.1 Immunogenicity Sampling  
Blood samples for detection of ADA (including NAb) will be collected prior to initiation (preferably within 30  minutes) of infusion of study treatment  on Day 1 and Day 15 and then 
on visits at Weeks 4, 8, and 12 (EOS/ET)  as specified in Table  14-1 and Section  6.1. 
Whole blood samples ( approximately 10 mL) will be collected and processed to obtain 
approximately 4 mL of plasma for ADA (including titer and NAb) detection at each time point. Samples should  be processed per detailed instructions in the laboratory m anual for collection 
by the c entral laboratory. The samples will be shipped to laboratories for ADA titer and NAb 
analysis by the c entral laboratory as detailed in the laboratory manual. 
Along with the immunogenicity sample, a time -matched blood sample (approximately 5 mL ) 
will be collected for the estimation of rituximab concentration. The evaluation of the samples 
will be performed to interpret safety and/or immunogenicity data appropriately, if needed. 
The central laboratory shipment address and assay laboratories contact information will be 
provided to the investigator prior to or during the initiation of the study. 
Further details on sample collection, processing, and shipment are provided in full in the 
laboratory manual. 
Page 239
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 61 6.2.2 Immunogenicity Assay  
Immunogenicity samples will be analyzed by designated analytical laboratory(ies) using 
validated methods. Analysis of ADA samples will follow a tiered approach of screening, 
confirmation, and titer determination.  Samples that are confirmed positive for ADA will be 
further tested for titer and NAb using validated assays.  
Immunological testing in human subject s will involve a multi -tiered approach as outlined 
below: 
Tier I Screening Assay : All the clinical samples for immunogenicity assessment will be 
subjected to a s creening assay. The methodology is based on the principle of capture of the 
ADA by the drug and detection by biotin- labelled drug, using ELISA. The test methodology 
may be modified after the method validation is completed. During method validation, an assay 
cut point is statistically determined. The samples that show a response equal to or above the 
pre-determined screening cut point will be called as ‚Äúscreening positive ‚Äù and the ones that 
show a response below the assay cut point will be called as ‚Äúnegative ‚Äù.  
Tier II Confirmation Assay : All the clinical samples that are ‚Äú screening positive ‚Äù will be 
subjected to a confirmation assay. This will involve the inhibition of the response seen in the 
screening assay with high concentration of drug. The assay format is an adaptation of the 
screening assay, where the samples are spiked with phosphate-buffered saline or drug and 
incubated for 1 hour at 37¬∞C prior to evaluation according to the s creening assay procedure. 
The samples that show a response equal to or above the pre -determined confirmatory cut point 
will be called as ‚Äúconfirmed positive ‚Äù and the ones that show a response below the assay cut 
point will be called as ‚Äúnegative ‚Äù.  
Tier III Titer Determination : It is the semi -quantitative assay where titers of the confirmed 
ADA- positive samples will be evaluated with respect to a previously es tablished titer cut point. 
During the clinical sample analysis, serial 2- fold dilutions of confirmed positive samples will 
be performed and the reciprocal of the dilution able to yield a response at or above the titration cut point will be reported as the titer of the ADAs.  
Tier IV Neutralizing Antibodies Assay : This is based on the principle that any sample 
containing NAbs would reduce or abolish the biological activity associated with a known 
concentration of drug product used in a cell -based NAb assay. This is based on the mechanism 
Page 240
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 62 of action of the drug (rituximab) and is used to characterize the neutralizing activity of the 
confirmed ADA -positive samples. Rituximab induces CDC . The ability of the ADA to 
neutralize the CDC activity of rituximab will be assessed in a cell -based assay. This assay is 
developed and will be validated prior to clinical sample analysis. This assay is a 
characterization of the confirmed ADAs.  
The diagrammatic representation of the immunogenicity assessment of rituximab in the clinical 
study is shown  in Figure 6-1. 
Figure 6-1: Flow Diagram for the Evaluation and Characterization of Anti- Drug 
Antibodies  
 
Abbreviation: ADA, anti -drug antibody.  
 
Comprehensive information regarding validity, specificity, and sensitivity of immunogenicity 
assays used in this study will be provided in a separate report.  
6.3 Safety Assessme nts 
The safety endpoints of this study are as follows :  
‚Ä¢ Incidence of TEAEs  and SAEs . 
Page 241
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 63 ‚Ä¢ Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs. 
Other safety endpoints will include  the following:  
‚Ä¢ Clinical laboratory parameters  
‚Ä¢ Vital signs 
‚Ä¢ Twelve -lead ECG  
‚Ä¢ Physical examination  
Definitions  
Infusion- related Reactions 
Infusion- related reactions are defined as a group of acute reactions to the allergen (or 
therapeutic protein for this study) that occur during or shortly after drug infusion and generally 
resolve completely within 24 hours of completion of infusion. 
Signs/symptoms may include  the following: a llergic reaction (including drug fever), a rthralgia  
(joint pain), bronchospasm, cough, dizziness, dyspnea (shortness of breath) , fatigue (asthenia, 
lethargy, malaise) , headache, hypertension, hypotension, m yalgia (muscle pain) , nausea, 
pruritis/itching , rash/desquamation , rigors/chills , sweating (diaphoresis) , tachycardia, t umor 
pain (onset or exacerbation of tumor pain due to treatment) , urticaria (hives, welts, wheals) , 
and vomiting  (Doessegger L  and Banholzer ML 2015). 
Hypersensitivity Reactions 
Any AE, which occurs 24 hours of completion of infusion and with clinical or clinical 
laboratory (if performed) features suggesting an immunoallergic mechanism and without any 
other supported alternative explanation and not fulfilling the provided definition of 
anaphylactic reaction. 
Hypersensitivity reactions to biologic agents are less common than standard IRRs . Although 
some clinical signs and symptoms are more unique to hypersensitivity reactions, many are 
similar. Hypersensitivity and standard IRRs  can have gastrointestinal symptoms, dyspnea, 
flushing, pruritus, and back pain. Symptoms that are more suggestive of a hypersensitivity reaction would include urticaria, wheezing, frequent coughing, and anaphylactic symptoms  
(Khan  DA 2016). 
Page 242
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 64 Anaphylaxis 
Anaphylaxis is highly likely when any 1 of the following 3 criteria ( criteria of the National 
Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network), which 
will be applied for diagnosing anaphylaxis  (Sampson HA  2006) are fulfilled based on the 
principal investigator ‚Äôs discretion or clinical evaluation:  
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (e .g., generalized hives, pruritus or flushing, swollen 
lips-tongue- uvula) AND AT LEAST 1 OF THE FOLLOWING: 
a. Respiratory compromise (e .g., dyspnea, wheeze -bronchospasm, stridor, reduced 
peak expiratory flow or hypoxemia). 
b. Reduced BP or associated symptoms of end  organ dysfunction (e .g., hypotonia 
[collapse], syncope, incontinence). 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that subject  (minutes to several hours):  
a. Involvement of the skin mucosal tissue (e.g., generalized hives, itch -flush, 
swollen lips-tongue-uvula). 
b. Respiratory compromise (e .g., dyspnea, wheeze -bronchospasm, stridor, reduced 
peak expiratory flow, hypoxemia). 
c. Reduced BP or associated symptoms (e.g., hypotonia [collapse], s yncope, 
incontinence). 
d. Persistent gastrointestinal symptoms (e .g., crampy abdominal pain, vomiting). 
3. Reduced BP after exposure to known allergen for that subject  (minutes to several 
hours): 
a. Infants and children: low systolic BP (age specific) or greater than 30% decrease 
in systolic BP ( this study is going to be conducted in adult subject  population, 
hence this criterion will not be applicable here).  
b. Adults: systolic BP of less than 90 mmHg or greater than 30% decrease from 
that person‚Äôs baseline. 
Note: Abo ve differentiating features of IRRs , hypersensi tivity  and anaphylaxis are 
recommendations based on the literature  (Doessegger L  and Banholzer ML  2015, Khan  DA 
Page 243
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 65 2016, Sampson HA  2006). The i nvestigator should use his/her clinical judgment to document 
it as IRRs and/or hypersensiti vity reactions  and/or anaphylaxis. 
The timing and frequency of safety assessments are described in Section  6.1. 
6.3.1 Adverse Events 
6.3.1.1  Definitions  
The definitions for AEs , SAEs , and TEAEs  are given below. It is of the utmost importance that 
all site personnel  involved in the study are familiar with the content  of this section. The 
principal investigator is responsible for ensuring this. 
6.3.1.1.1  Adverse Event /Reaction  
An AE is defined as any untoward medical occurrence in a subject, or clinical investigation 
subject administered a pharmaceutical product, and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, 
symptom, or disease temporally associated with the use of a study treatment, whether or not 
related to the study treatment. 
Any relevant observations made at the screening visit (prior to signing the ICF ) are to be 
recorded as a preexisting  condition; an AE will only be recorded if there is a worsening of the 
preexisting  condition during study conduct with regards to nature, severity, or frequency.  
An ADR is an untoward and unintended response to a study treatment related to any dose 
administered.  All AEs judged by either the reporting investigator or the sponsor as having a 
reasonable causal relationship to a medicinal product qualify as ADRs. The expression of 
‚Äúreasonable causal relationship‚Äù means to convey in general that there are facts or arguments 
meant to suggest a causal relationship.  
A pre -treatment event is defined as any untoward medical occurrence in a clinical investigation 
subject who has signed informed consent to participate in a study but prior to administration of any study drug; it does not necessarily have to have a causal relationship with study 
participation.  
Page 244
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 66 Serious Adverse Event  
An SAE is defined as an AE that results in 1 of the following outcomes: 
‚Ä¢ Results in death.  
Death is not an AE/SAE itself, but an outcome. The cause of the death is an  AE, which 
resulted in death.  
‚Ä¢ Is life -threatening. 
Life-threatening means that the subject was at immediate risk of death at the time of the 
SAE, it does not refer to an SAE that hypothetically might have caused death if it were 
more severe.  
‚Ä¢ Requires in -subject hospitalization or prolongs existing hospitalization (This does not 
include prolonged hospitalization for study purposes). 
Hospitalization is defined as at least 1 overnight formal admission into hospital, usually to 
perform additional tests, provide treatment that it is not possible to provide at home and/or 
to allow specific monitoring of the subject due to their unstable medical condition. Current 
hospitalization due to preplanned hospitalizations (known already prior to signing the ICF) 
will not be considered an SAE, unless any of the above criteria are fulfilled over the course 
of the hospitalization due to unplanned complications. Following the initial discharge from 
hospital, subsequent hospitalizations are to be considered an SAE. ‚ÄúSocial‚Äù hospitalization, 
defined as administrative impossibility to discharge the subject is not necessarily an SAE. 
Complica tions that occur during hospitalization are AEs unless they would qualify as an 
SAE for any of the above criteria. If the complication delays the subject‚Äôs release from hospital, then the AE becomes an SAE. Hospitalizations due to diagnostic procedures 
which are not performed due to an AE are not regarded as SAE. 
‚Ä¢ Results in persistent or significant disability/incapacity.  
The term significant disability refers to any condition that impairs physical/psychological well-being to the extent that the subject is unable to function normally. Physical disability 
may include, but is not limited to, permanent disability of locomotion or motility, but also systemic permanent dysfunction as development of heart failure, liver insufficiency , or 
pulmonary fibrosis. 
‚Ä¢ Is a congenital anomaly/birth defect. 
Page 245
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 67 ‚Ä¢ Is an important medical event.  
Important medical events that may not result in death, be life -threatening , or require 
hospitalization may be considered an SAE when, based upon appropriate medical judgment 
they may jeopardize  the subject or the subject may require medical or surgical intervention 
to prevent 1 of the outcomes listed in this definition.  
6.3.1.1.2  Treatment -Emergent Adverse Event  
Treatment -emergent AEs are  defined as any AE occurring or worsening on or after the first 
dose of study medication.  
6.3.1.2  Recording of Adverse Events 
Any relevant observations made at the screening visit (prior to signing the ICF) are to be 
recorded as a preexisting  condition. For the purposes of this study, any detrimental change in 
the subject ‚Äôs condition, after signing the ICF  and up to completion of the  26-week  study period, 
should be considered as a TEAE/SAE.   
The following variables will be recorded for each AE: verbatim/AE description and date for AE start and stop, severity, seriousness, causality rating, whether or not the AE caused the 
subject to discontinue, action taken with the study treatment, and the outcome. If the severity 
of the event  changes, the ev ent with the highest severity  will be recorded . 
Serious AEs and TEAEs will be recorded starting after signing of the ICF . All SAEs and AEs 
have to be recorded, whether or not considered causally related to the study treatment  or to the 
study procedure(s). 
All ongoing nonserious AEs should be followed up until resolution or stabilization  or the 
EOS/ET visit, whichever occurs first, with the exception of any ongoing treatment -related 
nonserious AEs that should be followed until that  AE is stabilized , resolved, or, in the 
investigator's opinion, the AE is unlikely to resolve due to the subject's underlying condition. 
All ongoing SAEs should be followed up until resolution or stabilization /or until a pre -defined 
outcome is reached .  
Page 246
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 68 Note: Outcome information received on on- going SAE beyond the date of data base lock, will 
be captured in safety database and repor ted as follow- up report in the form of individual case 
safety report.  
At any time after the additional follow -up visit, if an investigator learns of an SAE that can be 
reasonably related to study treatment , he/she should promptly notify the sponsor/designee. 
6.3.1.3  Assessment  of Severity 
Whenever possible, the intensity of clinical AEs will be graded according to National Cancer 
Institute  (NCI) CTCAE (Version  5.0 or any latest version ) grading system. Adverse events not 
listed in the NCI  CTCAE grading system will be graded on a 5- point scale (mild, moderate, 
severe, life-threatening, and death) as described below, and reported in detail as indicated on 
the eCRF.  
Severity Grading for A dverse E vents Listed in NCI  CTCAE ( Version 5.0 or any L atest 
Version ): 
‚Ä¢ Grade 1: Mild : asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
‚Ä¢ Grade 2: Moderate : minimal, local, or noninvasive intervention indicated; limiting age 
appropriate instrumental activities of daily living (ADL) (Instrumental ADL refer s to 
preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc). 
‚Ä¢ Grade 3: Severe: or medically significant but not immediately life -threatening; 
hospitalization  or prolongation of hospitalization  indicated; disabling; limiting self -care 
ADL  (Self-care ADL refer s to bathing, dressing and undressing, feeding self, using the 
toilet, taking medications, and not bedridden).  
‚Ä¢ Grade 4: Life -threatening : life-threatening consequence; urgent intervention indicated. 
‚Ä¢ Grade 5: death related to AE.  
Note the distinction between the severity and the seriousness of an AE. A severe event is not necessarily an SAE. For example, a headache may be severe (interferes significantly with 
subject‚Äôs usual function) but would not be classified as serious unless it meets 1 of the criteria 
for SAEs, listed in Sect ion 6.3.1.1.1. 
Page 247
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 69 6.3.1.4  Assessment  of Causality  
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of AE/SA E. The investigator will use clinical judgment to determine the 
relationship. Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administra tion will be considered and investigated. The i nvestigator will also consult the IB 
and/or product i nformation, for marketed products, in his/her assessment. There may be 
situations in which an SAE has occurred, and the i nvestigator has minimal information to 
include in the initial report in the eCRF. However, it is very important that the investigator 
always make an assessment of  causality for every event before the initial transmission of 
the SAE data via eCRF. The investigator may change his/her opinion of causality in light of 
follow -up information and change the assessment in the eCRF, which will trigger an alert to 
the sponsor‚Äôs designated safety services. The causality assessment is 1 of the criteria used when 
determining regulatory reporting requirements.  
The following ‚Äúbinary‚Äù decision choice will be used by the investigator to describe the causality assessment : 
‚Ä¢ Reasonable possibility of relatedness (i.e., related)  
‚Ä¢ No reasonable possibility of relatedness (i .e., not r elated)  
The term ‚Äúreasonable possibility of relatedness‚Äù is meant to convey, in general, that there is 
enough evidence or argument to suggest the causal relationship. The investigator should 
consider the following  before reaching  a decision on causality assessment:  
‚Ä¢ Time relationship between study treatment intake and event‚Äôs onset; 
‚Ä¢ Dechallenge ; 
‚Ä¢ Rechallenge ; 
‚Ä¢ Medical history ; 
‚Ä¢ Study treatment ; 
‚Ä¢ Mechanism of action of study treatment; 
‚Ä¢ Class effect ; 
Page 248
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 70 ‚Ä¢ Concomitant treatments in use ; 
‚Ä¢ Withdrawal of study treatment; 
‚Ä¢ Lack of efficacy/worsening of existing condition; 
‚Ä¢ Erroneous treatment with study medication or concomitant medication; 
‚Ä¢ Protocol-r elated process.  
Action taken with study treatment  due to the AE: 
‚Ä¢ Dose not changed; 
‚Ä¢ Drug interruption ; 
‚Ä¢ Drug withdrawn; 
‚Ä¢ Unknown; 
‚Ä¢ Not applicable. 
Outcome : 
Each single AE must be rated by choosing 1 of the following: 
‚Ä¢ Recovered/resolved ; 
‚Ä¢ Recovering/resolving; 
‚Ä¢ Not recovered/not resolved; 
‚Ä¢ Recovered with sequelae/resolved with sequelae ; 
‚Ä¢ Fatal ; 
‚Ä¢ Unknown. 
Note: If an event is stabilized per opinion of the investigator, then outcome option of ‚ÄúNot 
recovered/not resolved‚Äù to be selected in drop down list of outcome in eCRF. However, in 
AE/SAE description free filed of eCRF, investigator has to mention the event is assessed as ‚ÄúStabilized‚Äù on a given date.  
The investigator and the sponsor (or sponsor‚Äôs designee) will review each SAE report and the 
sponsor/CRO will evaluate the seriousness and the causal relationship of the event to study 
intervention. In addition, the s ponsor (or sponsor ‚Äôs designated agent) will evaluate the 
Page 249
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 71 expectedness accordi ng to the reference document (IB or SmPC  or PI ). Based on the 
investigator and sponsor ‚Äôs assessment of the event, a decision will be made concerning the 
need for further action. 
6.3.1.5  Reporting of Serious Adverse Events 
Investigators and other site personnel mus t inform as appropriate to the sponsor‚Äôs designated 
safety services of any SAEs that occur (whether or not attributable to the study treatment ) in 
the course of the study within 1 day (24 hours) (i .e., immediately but no later than the end of 
the next calendar day) of when he or she becomes aware of it.  
Follow- up information on SAEs must also be reported by the investigator to the sponsor‚Äôs 
designated safety services within the same time frames.  
If a n onserious AE becomes serious, this and other relevant follow -up information must also 
be provided to sponsor‚Äôs designated safety services within 24 hours as described above. 
All SAEs must be reported, whether or not considered causally related to the study treatment  
or study procedure(s). All SAEs will be recorded in the e CRF ; paper forms  will be used as a 
back -up only if the eCRF is unavailable. The investigator is responsible for informing the 
IEC/IRB  of the SAE per local requirements.  
Source documents re levant for the SAE must be reported upon request by sponsor‚Äôs designated 
safety services. Due to data protection laws, please ensure redaction of the subject‚Äôs identifiers 
(name, address, and date of birth [only year of birth is allowed]) from the discharge summary, 
autopsy report, laboratory reports, and any other documents/reports when sending to the 
sponsor‚Äôs designated safety services.  
The completed and signed SAE or pregnancy report f orm must be attached to the email. A 
notification email of the event describing it in the email text is not sufficient.  
There may be situations when an SAE has occurred, and the investigator has minimal information to include in the initial SAE report. However, it is very important that the 
investigator always makes an assessment of causality for every event prior to transmission of 
the SAE report f orm. Minimum criteria are identifiable subject (number), a suspect product 
(i.e., study treatment or concomitant medication), an identifiable reporting source 
(investigator/study site identification), and an event or outcome that can be identified as 
Page 250
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 72 serious. The investigator may change his/her opinion of causality in the light of foll ow-up 
information, amending the SAE r eport form accordingly. The causality assessment is 1 of the 
criteria used when determining regulatory reporting requirements for SAEs.  
When an SAE is discovered by the site or is identified by a clinical research associate during 
site visits, SAEs will be entered by the site members into the eCRF, which contains specific 
questions for events regarded as serious. The designated personnel will receive the alert through automated email notification.  
The sponsor/designee re presentative will work with the investigator to compile all the 
necessary information and ensure that the appropriate sponsor representative receives a report 
within 1  calendar day (24 hours) for all fatal and life -threatening cases and within 5  calendar 
days for all other SAEs  per the applicable local regulatory guidelines. All SAEs and follow -up 
information on the SAEs are to be reported to Pharmacovigilance in 24 hours regardless 
of seriousness criteria. 
Prompt notification of SAEs to  the sponsor/des ignee, as described above, is essential so that 
regulatory requirements and ethical obligations to the subjects involved in the study can be 
met. The investigator is responsible for informing the IEC/IRB of the SAE per local 
requirements.  Unblinding relating to s uspected unexpected serious adverse reaction s 
(SUSARs) (if required) will be performed by the sponsor/designee in accordance with standard 
operating procedures (SOPs), working practice documents, and documented study- specific 
procedures. 
6.3.1.6  Suspected Unexpected Serious Adverse Reactions 
Any AE that is ser ious, associated with the use of the study intervention, and unexpected  
(SUSAR) has additional reporting requirements as described below. 
‚Ä¢ If the SUSAR is fatal or life -threatening, associated with study intervention, and 
unexpected, regulatory authorities and IEC/IRB will be notified within 7  calendar days 
after the sponsor learns of the event. Additional follow-up (cause of death, autopsy report, 
and hospital report) information should be reported within an additional 8 days (15 days 
total).  
Page 251
CI
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 73 ‚Ä¢ If the SUSAR is not fatal or life -threatening but is otherwise serious, associated with study 
intervention, and unexpected, regulatory authorities and IEC/IRB will be notified within 
15 calendar days after the sponsor learns of the event. 
The sponsor‚Äôs designated safety services will also provide periodic and annual safety updates 
to the regulatory authorities, IEC/IRB responsible for the study, and investigators per local 
regulations. These updates will include information on SUSARs and other relevant safety 
findings. 
6.3.2 Abnormal Laboratory Values/Vital Signs 
Measurements/Electrocardiograms 
Laboratory/vital signs/ECG abnormalities should be reported as an AE/SAE if any 1 of the 
following criteria is met: 
‚Ä¢ Result is associated with signs/symptoms; 
‚Ä¢ Requires additional diagnostic testing and/or interventions ; 
‚Ä¢ Leads to a change in dose, discontinuation of, or interruption to the study treatment . 
Repeats of an abnormal test result without any of the above criteria do not constitute an AE. 
Any test result determined to be an error is not required to be reported as an AE. 
6.3.3 Deaths 
Should a death occur within the study period, an AE f orm and an SAE report f orm should be 
completed, detailing the AE that resulted in the death (Note : death is an outcome, not an event). 
The SAE must be reported to the sponsor or the sponsor‚Äôs designated safety services within 
24 hours as described in Section  6.3.1.5. 
Expedited reporting is determined by the CRO depending on the information provided by the 
site, e.g., AEs that are fatal/life -threatening and related to the study drug would be considered 
as expedited and reported to regulatory authorities  and IEC/IRB within 7  calendar days.  
Adverse events with any other seriousness criteria and relatedness would be reported to 
regulatory authorities  and IEC/IRB within 15 calendar days.  
Page 252
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 74 6.3.4 Clinical Laboratory As sessments  
Clinical laboratory assessments will be performed as indicated in Table  14-1. Hematology, 
biochemistry, and urinalysis will be conducted at the following visits: screening, on Day  1, 
Day 15, and at  Week s 4, 8, 12 (EOS/ET) , and 26 (additional follow -up). S erum pregnancy test  
will be conducted at s creening , Week  12 (EOS/ET), and Week  26 (additional follow -up) visits . 
Urine pregnancy test will be conducted on Day 1 prior to randomization , and D ay 15 (before 
dosing), at Week  4 and Week  8 visits. 
Hematology, bio chemistry , urinalysis, and pregnancy tests will be performed by the local 
laboratory according to local practice. Local laboratory normal ranges will be collected prior 
to first subject first visit at each site and provided to data management via the study team. 
Laboratory resu lts collected from the local laboratory should be entered in the eCRF by the 
investigator. The following parameters will be assessed:  
‚Ä¢ Hematology: red blood cell count, white blood cell count with differential count and percentages  (including absolute neutr ophil count), total hemoglobin, hematocrit, platelet 
count, and prothrombin time. 
‚Ä¢ Biochemistry: creatinine, blood urea nitrogen, fasting serum glucose, aspartate 
aminotransferase, alanine aminotransferase, gamma- glutamyl transpeptidase, total 
bilirubin, albumin, chloride, calcium, phosphorous, uric acid, total protein, sodium , and 
potassium.  
‚Ä¢ Serum IgG  and IgM. 
‚Ä¢ Urinalysis (specific gravity, pH, protein, glucose, and blood). 
‚Ä¢ Pregnancy test: serum Œ≤ -hCG test and urine pregnancy test for WOCBP . 
‚Ä¢ Serum FSH for po stmenopausal women.  
Note: Per CTFG 2014 guidelines, a postmenopausal state is defined as no menses for 
12 months without an alternative medical cause. A high FSH level in postmenopausal women 
is to be used to confirm a postmenopausal state in women not using hormonal contraception 
or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a 
single FSH measurement is insufficient. Hence, in such cases or in some other cases in which 
if menopausal status is difficult to confirm, then investigators are advised to investigate further 
to rule out childbearing potential along with serum FSH. 
Page 253
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 75 Blood and urine collection and blood sample preparation will be performed according to 
procedures from the local laboratories.  
6.3.5 Physical Examination 
Complete physical examinations will be performed as indicated in Table  14-1. The following 
parameters and body systems will be examined  and any abnormali ties described: weight, 
height (at screening  visit only), general appearance, skin ( e.g., presence of rash), head, eyes, 
ears, nose, throat, lungs (auscultation), heart (auscultation for presence of murmurs, gallops, 
rubs), extremity exam for the presence of peripheral edema, abdominal (palpation and 
auscultation), and neurologic (mental status and motor and sensory function). The physical 
examination must include a thorough assessment of the lymph nodes, liver , and spleen. The 
genitourinary system may be excluded unless there are signs or symptoms involving that system. Any clinically significant changes from the screening visit after initial dosing with 
study treatment should be recorded as AEs.  
6.3.6 Vital Sign  Measurements 
Vital signs, including heart rate, seated BP, respiration rate , and oral body temperature, will be 
measured as detailed in Table  14-1 and in the event of an IRR. 
Blood pressure will be measured in the subject‚Äôs arm and recorded to the nearest mmHg after 
the subject has been seated quietly for at least 2  minutes. The same arm and position should be 
used throughout the study, using an appropriate cuff size. All BP  readings should be measur ed 
after resting for at least 5  minutes. When the timing of these measurements coincides with 
blood collection, the BP  and heart rate should be obtained first. 
Vital signs are to be obtained prior to each study treatment  infusion, every 30 minutes 
(¬± 5 min utes) during infusion, at the end of infusion, and as clinically indicated. In the event 
of hypersensitivity reaction , vital signs should be obtained at additional time  points until 
recovery per investigator judgment. 
6.3.7 12-L ead E lectrocardiogram  
Twelve -lead ECGs will be performed as indicated in  Table  14-1 unde r medical supervision. 
Before recording, subjects should be resting in a quiet supervised setting with minimal 
Page 254
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 76 stimulation (e .g., no television, loud music, and computer games) and lie in a  resting position 
for 10 minutes before ECG recording. 
All ECGs are to be read locally with local ECG equipment by an appropriately qualified and 
experienced ECG reader at the study site.  
Corrected QT interval ( QTc) value will be calculated using the Fridericia formula 
(QTc  = QT/(RR-1/3), QTc should be expressed in milliseconds, the provided formula assumes 
QT also in milliseconds and RR in seconds. The QTc interval will be automatically calculated. 
In the case of clinically significant ECG abnormalities, the investigator should report these as 
an AE if not due to a preexisting condition or if a preexisting condition worsens in frequency 
or intensity. 
6.3.8 Viral Disease Screening  
Subjects will be tested for HIV , hepatitis B, and /or hepatitis  C to determine eligibility  at 
screening visit . 
HBsAg,  HBc Ab, HCV , and HIV are to be determined by each site‚Äôs local laboratory . 
Note: For HBcAb, site is requested to perform HBcAb IgG and HBcAb IgM. If any of these 2 results is  positive, then the subject will be considered as screen failure.  
6.4 Pregnancy 
Pregnancy itself is not regarded as an AE unless there is a suspicion that the st udy treatment 
may have interfered with the effectiveness of a contraceptive medication. If a pregnancy is reported for a subject, no further study treatment will be administered to this subject and the 
outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth, or 
congenital abnormality) must be followed up and documented. Follow -up should be done up 
to delivery and after the examination of the newborn a follow -up report should be sent with 
any new information regarding the pregnancy and the outcome of the newborn. 
All congenital abnormalities/birth defects should be classified as SAEs. Spontaneous 
miscarriages should also be reported and handled as SAEs. Elective abortions without complications should not be handled as SAEs but should be reported as an AE . All outcomes 
of pregnancy must be reported to the sponsor on a pregnancy outcomes report f orm. 
Page 255
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 77 Pregnancy outcomes must be collected for the female partners of any males who took study 
treatment in this study. Consent to report information regarding these pregnancy outcomes 
should be obtained from the female partner.  
Pregnancies must be reported to the sponsor or sponsor‚Äôs designated safety services using the 
reporting details provided in Section  6.3.1.5 within 24 hours of awareness.  
6.5 Blood Loss During the S tudy  
For the safety evaluation, approximately 10 mL of blood will be withdrawn from the subjects 
at each time point. A total of approximately 145 mL of blood will be collected per subject 
during the study for immunogenicity , for estimation of rituximab concentration , and safety 
evaluation as mentioned in Table  6-1. 
Table  6-1: Blood Loss During the Study  
Abbreviations: ADA , anti-drug antibody; NAb , neutralizing antibod y. 
Note: For safety evaluation, more than 10  mL of blood can be withdrawn based on the site/local laboratory 
practice and will not be considered as a deviation.  
 Time Points  Safety 
Evaluation 
(Laboratory)  ADA and NAb 
Evaluation  For Estimation of 
Rituximab Concentration  
(Approx imately ) Total Volume 
of Blood Loss  
Screening  10 mL  -  10 mL  
Week 1/Day 1  10 mL  10 mL  5 mL  25 mL  
Week 2/Day 15  10 mL  10 mL  5 mL  25 mL  
Week 4  10 mL  10 mL  5 mL  25 mL  
Week 8  10 mL  10 mL  5 mL 25 mL  
Week 12  10 mL  10 mL  5 mL  25 mL  
Week 26  10 mL  - - 10 mL 
Total volume of blood 
loss 70 mL  50 mL  25 mL  145 mL 
Page 256
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 78 7 Statistical and Analytical Plan  
7.1 Sample Size Calculations  
 
 
7.2 Analysis Sets 
The safety population will include all subjects who are randomized and receive at least 1 dose 
of study treatment. 
Immunogenicity population will include all subjects with at least 1 post- dose ADA assessment 
result available.  
Analyses of safety parameters will be based on the safety population , and immunogenicity 
parameters (ADA and N Ab) will be based on the immunogenicity population. 
7.3 Description of Subgroups to be Analyzed 
Immunogenicity and key safety parameters will be presented overall and by region, as 
appropriate. 
7.4 Statistical Analysis Methodology  
7.4.1 General Principles  
The statistical analysis will be perfo rmed using SAS Version  9.4 or later . 
The immunogenicity and safety data will be analyzed descriptively. All individual data as well 
as results of statistical analyses, whether explicitly discussed in the following sections or not, 
will be presented in individual subject data listings and statistical summary tables.  
Page 257
CI
CI
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 79 In general, continuous variables will be summarized using the following standard descriptive 
summary statistics: number of observations, arithmetic mean, standard deviation, minimum, 
median, and maximum. Categorical variables will be displayed by means of frequency tables 
including percentages. 
Baseline is defined as the last non -missing pre -dose assessment. Overall summaries and 
analyses will be performed based on data pooled from all sites.  
A SAP will be prepared and finalized before the clinical study database is closed . 
7.4.2 Missing Data  
All efforts will be made to ensure that all values are populated for start and stop date of 
AE/concomitant medication  and severity and causality of AE. In case of any missing or partial 
dates for AEs, concomitant medication , and any other dates required for analysis still exists, 
then those will be imputed in an appropriate conservative way. For AEs, missing severity and 
relationship with treatment, if an y, will also be imputed in an appropriate conservative way. 
Further details  will be described in the SAP.  
Other missing values will not be imputed, unless otherwise specified  in each analysis section . 
7.4.3 Demographic and Baseline Characteristics  
Demographic and b aseline characteristics will be analyzed in a descriptive fashion and results 
will be presented overall and by treatment arm . 
7.4.4 Subject Disposition  
The following will be summarized (overall and by treatment arm where applicable):  
‚Ä¢ Subjects screened.  
‚Ä¢ Subjects randomized . 
‚Ä¢ Subjects in the safety analysis set.  
‚Ä¢ Subjects completing the study/withdrawing early (including withdrawal reason). 
7.4.5 Immunogenicity Analysis  
The immunogenicity  endpoint of this study is the incidence of ADA, including titer and NAb.  
Page 258
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 80 Immunogenicity data (ADA and N Ab) will be summarized and analyzed descriptively for each 
scheduled protocol assessment time point by treatment arm  and overall. 
Further details of the  analysis will be described in the SAP.  
7.4.6 Safety Analysis  
The safety analysis will be based on the safety population and will be analyzed according to 
the treatment they actually received. Detail methods will be described in the SAP.  
The safety endpoints are as follows: 
‚Ä¢ Incidence of AEs. 
‚Ä¢ Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs. 
Other safety endpoints will include  the following:  
‚Ä¢ Clinical laboratory parameters  
‚Ä¢ Vital signs  
‚Ä¢ Twelve -lead ECG  
‚Ä¢ Physical examination.  
Treatment -emergent AEs will be described using descriptive statistics and  coded according to 
the Medical Dictionary for Regulatory Activities (MedDRA), system organ class and MedDRA 
preferred term, graded according to CTCAE  (Version 5.0 or any latest version), by tre atment 
arm and overall. TEAEs observed, will be summarized separately by treatment arm . 
Treatment -related TEAEs and SAEs, TEAEs leading to study discontinuation, and deaths will 
be also summarized by treatment arm. 
Incidence of anaphylactic reactions, hypersensitivity reactions, and IRRs  will be summarized 
by treatment arm  and overall. 
Clinical safety laboratory data will be presented by treatment arm and overall. For each visit, 
the actual result and the change from baseline wil l be presented. Shift tables for values outside 
the clinical normal ity status  will be presented as appropriate.  
Page 259
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 81 Otherwise, safety data will be presented in tabular and/or graphical format and summarized 
descriptively, where appropriate. For continuous meas urements (laboratory and vital signs 
data), change from baseline will be additionally summarized by treatment arm and visit.  
Subject listings will be produced for all safety endpoints. 
7.4.7 Interim Analyses  
There will be no interim analysis  in this study . 
Page 260
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 82 8 Quality Control and Quality Assurance 
This study will be conducted according to the International Council for Harmonisation (ICH) 
E6(R2) risk and quality processes described in  the applicable procedural documents . The 
quality management approach to be implemented in this study will be documented and will 
comply with the  current ICH guidance on quality and risk management. 
8.1 Case Report Forms/Source Data Handling  
An eCRF is required and should be completed for each included subject. The investigator shall 
be provided with standardized e CRF and shall ensure that all data from subject visits are 
promptly entered into the eCRF in accordance with the specific instructi ons given. 
The investigator must maintain source documents  at the study site to support the data entered 
into the eCRF. Source documents are considered to be all information in original records and certified copies of original records of clinical findings,  observations, data , or other activities in 
a clinical study necessary for the reconstruction and evaluation of the study, such as laboratory reports, e dges, consultation reports, complete medical history , and physical examination 
reports. 
The investigator  has ultimate responsibility for the collection and reporting of all clinical, 
safety , and laboratory data entered on the eCRF and any other data collection forms (source 
documents) and ensuring that they are accurate, authentic/original, attributable, com plete, 
consistent, legible, timely (contemporaneous), enduring, and available when required. The 
eCRF must be signed by the investigator or by an authorized staff member to attest that the 
data contained on the eCRF is true.  
8.2 Data Management 
A data management plan will be prepared before data collection initiates. The data management 
plan will describe all study specifics functions, processes, and specifications for data 
collection, cleaning, and validation. The eCRFs will include programmable edits to obtai n 
immediate feedback if data are missing, out of range, illogical , or potentially erroneous. 
Concurrent manual data review will be performed based on parameters dictated by the plan. Ad hoc queries will be generated within the electronic data capture  syste m and followed up for 
resolution. Data quality will be enhanced through a series of programmed data quality checks that automatically detect out-of- range or anomalous data. Data collection and entry is the 
Page 261
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 83 responsibility of CRO that will develop a quality control plan to assure that the data entered in 
the eCRFs reflects the source documents maintained on site. Entered data will be verified by 
the clinical monitor/data manager/designee who will query the site for potential discrepancies. 
The site investigat or or designee will be responsible for resolution of queries. Coding of 
medical history , AEs, and concurrent conditions  will be performed using latest version of 
MedDRA and coding of prior and concomitant medications and therapies will be performed 
using t he current version of World Health Organization Drug (WHODRUG)  Dictionary . The 
eCRFs and any supporting documentation should be available for retrieval or review at any given time. 
As part of the responsibilities assumed by participating in the study, the investigator agrees to 
maintain adequate case histories for the subjects treated as part of the research under this 
protocol. The investigator agrees to maintain accurate e CRFs and source documentation as part 
of the case histories. These source documents may include laboratory reports, ECG strips , etc. 
Investigative site personnel will enter subject data into  the electronic data capture system . The 
analysis data sets will be a combi nation of these data and data from other sources (e.g., 
laboratory data).  
Clinical data management will be performed in accordance with applicable  standards and 
data cleaning procedures to ensure the integrity of the data, e .g., removing errors and 
inconsistencies in the data. 
After database lock, e ach investigator will receive a compact disc/digital versatile disc ( DVD) 
with portable document format (PDF ) files for the subjects enrolled at their site and the sponsor 
will receive a Master DVD of all project data. These files will contain all of their site specific 
eCRF data as entered into Medidata Rave
¬Æ for the study, including full discrepancy and audit 
history. The Medidata Rave database will be stored by Medidata. In all cases, subject initials 
will not be collected or transmitted to the sponsor.  Additionally, a compact disc read -only 
memory copy of all of the study site‚Äôs data from the study will be created and sent to the 
sponsor for storage.  
Page 262
CI
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 84 9 Ethics  
9.1 Independent Ethics Committee or Institutional Review Board 
Prior to the start of the study, the investigator is responsible for ensuring that the protocol and 
consent form have been reviewed and approved by a releva nt IEC/IRB. Federal regulations 
and the ICH guidelines require that approval be obtained from an IRB/IEC before participation 
of human subjects in research studies. Before study onset, the protocol, informed consent, 
advertisements to be used for the recru itment of study subjects, and any other written 
information regarding this study to be provided to the subject must be approved by the 
IRB/IEC. Documentation of all IRB/IEC approvals and of the IRB/IEC compliance with ICH 
Harmonised T ripartite Guideline E6(R 2): Good Clinical Practice (GCP) will be maintained by 
the site and will be available for review by the sponsor or its designee.  
All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must 
identify the IRB/IEC name and address, th e clinical protocol by title or protocol number or 
both, and the date approval or a favorable opinion was granted. 
The investigator is responsible for providing written summaries of the progress and status of 
the study at intervals not exceeding 1 year or otherwise specified by the IRB/IEC. The 
investigator must promptly supply the sponsor or its designee , the IRB/IEC, and , where 
applicable, the institution,  with written reports on any changes significantly affecting the 
conduct of the study or increasing t he risk to subjects. 
9.2 Ethical Conduct of the Study  
This study shall be conducted in accordance with the provisions of the Declaration of Helsinki (October 1996) and all revisions thereof, and in accordance with FDA regulations (Code of 
Federal Regulations [ CFR] , Sections  312.50 and 312.56) and with ICH GCP ( Committee for 
Medicinal Products for Human Use [CH MP] 135/95). 
9.3 Subject Information and Consent 
The ICF will be used to explain the risks and benefits of study participation to the subject in 
simple terms before the subject will be entered into the study. The ICF contains a statement 
that the consent is freely given, that the subject is aware of the risks and benefits of entering 
Page 263
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 85 the study, and that the subject is free to withdraw from the study at any time . Written consent 
must be given by the subject, after the receipt of detailed information on the study.  
All ICFs must be available in the local languages required at the site and include subject 
information sheets/brochures that outline the study procedures. All ICFs must be signed and 
dated by the subject. 
For subjects who are unable to read and write, the subject information sheet and ICF should be 
read to the subject in his/her native language in the presence of an impartial witness who is 
literate and n ot affiliated with the study. The subject having understood the information given 
to him/her in the presence of an impartial witness will thumbprint the ICF and the same will be countersigned by the impartial witness. If the subject  cannot read, then an impartial witness 
will witness and attest the entire consent process and will be required to sign the consent form. Confirmation of a subject‚Äôs informed consent must also be documented in the subject‚Äôs medical 
record prior to any testing under this protoco l, including screening tests and assessments.  
The investigator is responsible for ensuring that informed consent is obtained from each 
subject, along with  their signatures and dates on the informed consent document , prior to the 
performance of any protocol  procedures including the administration of study drug. The 
investigator will provide each subject with a copy of the signed and dated consent form while 
the originals will be retained in the investigator‚Äôs records.  
The consent documents to be used for the  study shall include all the elements of informed 
consent as outlined in the applicable SOP (s), applicable regulatory requirements , and be 
reviewed and approved by the appropriate IEC/IRB prior to use. 
If a protocol amendment is required, the ICF may need to be revised to reflect the changes to 
the protocol. If the ICF is revised, it must be reviewed and approved by the appropriate 
IEC/IRB and signed by all subjects subsequently enrolled in the study as well as those currently 
participating in the stud y. 
Note: Sites are advised to follow local or country -specific guidelines while obtaining consent 
from the subject.  
Page 264
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 86 10 Investigator‚Äôs Obligations  
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on industry and government SOPs , working practice 
documents, or guidelines. Changes will be reported to the IRB/IEC but will not result in 
protocol amendments. 
10.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and ot her records will be identified in a 
manner designed to maintain subject confidentiality. All records will be kept in a secure storage 
area with limited access. Clinical information will not be released without the written 
permission of the subject , except as necessary for monitoring and auditing by the sponsor, its 
designee, the US FDA, local regulatory(ies), or the IRB/IEC.  
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confident ial information to other parties.  
10.2 Financial Disclosure and Obligations  
Investigators are required to provide financial disclosure information to allow the sponsor to 
submit the complete and accurate certification or disclosure statements required under 21 CFR 54. In addition, the investigator must provide to the sponsor /CRO a commitment to 
promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study.  
Neither the sp onsor nor CRO is financially responsible for further testing  or treatment of any 
medical condition that may be detected during the screening process. In addition, in the absence of specific arrangements, neither the sponsor nor CRO is financially responsib le for further 
treatment of the subject‚Äôs disease.  
Page 265
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 87 10.3 Investigator Documentation  
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R 2) 8.2 and 
Title 21 of the CFR by providing the following essential documents, including but not limited 
to: 
‚Ä¢ IRB/IEC approval 
‚Ä¢ Original investigator -signed investigator agreement page of the protocol. 
10.4 Study Conduct 
Dr. Reddy‚Äôs Laboratories  S.A./CRO shall implement and maintain quality control and quality 
assurance procedures with writ ten SOPs to ensure that the study is conducted, and data are 
generated, documented, and reported in compliance with the protocol, ICH  GCP and applicable 
regulatory requirements. 
The investigator may not deviate from the protocol without a formal protocol a mendment 
having been established and approved by an appropriate IEC/IRB, except when necessary to 
eliminate immediate hazards to the subject or when the change(s) involve(s) only logistical or administrative aspects of the study. Any deviations may result in the subject having to be 
withdrawn from the study and render that subject non evaluable.  
The investigator agrees that the study will be conducted according to the principles of ICH E6(R 2). The investigator will conduct all aspects of this study in accor dance with all national, 
state, and local laws or regulations.  Study information from this protocol will be posted on 
publicly available clinical trial registers before enrollment of subjects begin s. 
10.5 Adherence to Protocol  
The investigator agrees to conduct  the study as outlined in this protocol in accordance with 
ICH E6(R2) and all applicable guidelines and regulations. 
10.6 Adverse Events and Study Report Requirements  
By participating in this study, the investigator agrees to submit reports of SAEs  to the spons or 
and/or IRB/IEC , and to any other regulatory (if required by local regulatory and laws) 
according to the timeline  and methods outlined in the protocol. In addition, the investigator 
agrees to submit annual reports to the study site IRB/IEC as appropriate . 
Page 266
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 88 10.7 Records Retention 
To enable evaluations and/or audits from regulatory authorities or sponsor, the investigator 
agrees to keep records, including the identity of all participating subjects (sufficient 
information to link records, e.g., e CRFs and hospital records), all original signed ICFs, copies 
of all e CRFs, safety reporting forms, source documents, and detailed records of treatment 
disposition, and adequate documentation of relevant correspondence (e .g., letters, meeting 
minutes, telephone calls reports). The records should be retained by the investigator according 
to ICH, local regulations, or as specified in the clinical study agreement , whichever is longer. 
If the investigator becomes unable for any reason to continue to retain study records for the 
required period (e .g., retirement, relocation), sponsor and/or CRO should be prospectively 
notified. The study records must be transferred to a designee acceptable to the sponsor, such as an other investigator, another institution, or to an independent third party arranged by the 
sponsor. Investigator records must be kept for a minimum of 15 years after completion or discontinuation of the study or for longer if required by applicable local re gulations. The 
investigator must obtain sponsor's written permission before disposing of any records, even if retention requirements have been met.  
10.8 Publications 
The sponsor shall retain the ownership of all data. When the study is complete the sponsor 
shall arrange the analysis and tabulation of data. A CSR ( Section  11.4 ) shall then be prepared, 
which may be used for publication, presentation at scientific meetings , or submission to 
regulatory authorities. All proposed publications based on this study must be subject to the 
sponsor‚Äôs approval requirements. 
Page 267
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 89 11 Study Management 
11.1 Mon itoring  
11.1.1  Monitoring of the Study  
The investigator shall permit the site monitor to review study data as frequently as deemed 
necessary to ensure that data are being recorded in an adequate manner and that protocol 
adherence is satisfactory.  
The investigator shall access medical records for the monitor in order that entries in the eCRF may be verified. The investigator, as part of his/her responsibilities, is expected to cooperate 
with the sponsor/ CRO in ensuring that the study adheres to GCP requirements.  
The investigator may not recruit subjects into the study until such time that a visit, or with the agreement of the sponsor, or attendance at the investigator meeting, has been made by a 
sponsor/CRO monitor to conduct a detailed review of the protocol and eCRF.  
The clinical monitor, as a representative of the sponsor, has the obligation to follow the study 
closely. In doing so, the monitor will visit the investigator and study site at periodic intervals, 
in addition to maintaining necessary te lephone and letter contact. The monitor will maintain 
current personal knowledge of the study through observation, review of study records and 
source documentation, and discussion of the conduct of the study with the investigator and 
personnel. 
All aspects of the study will be carefully monitored, by the sponsor or its designee, for 
compliance with applicable government regulation with respect to current GCP and current 
standard operating procedures. 
Note: Due to COVID- 19 pandemic, provisions of remote monitoring have been added in the  
protocol ( Section 3.2, Study Conduct during the COVID- 19 Pandemic).  
11.1.2  Inspection of Records 
Investigators and institutions involved in the  study will permit study- related monitoring, audits, 
IRB/IEC review, and regulatory inspections by providing direct access to all study records. In 
the event of an audit, the investigator agrees to allow the sponsor, representatives of the 
sponsor, or a re gulatory agency access to all study records. 
Page 268
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 90 The investigator should promptly notify the sponsor and CRO of any audits scheduled by any 
regulatory authorities and promptly forward copies of any audit reports received to the sponsor.  
11.2 Management of Protocol Amendments and Deviations  
11.2.1  Protocol Amendments  
Before the start of the study, the study protocol and/or other relevant documents will be 
approved by the IEC/IRB/ competent a uthorities, in accordance with local legal requirements. 
The sponsor/authorized CRO representative must ensure that all ethical and legal requirements 
have been met before the first subject is enrolled in the study. Any changes in this research activity, e xcept those necessary to remove an apparent, immediate hazard to the subject, the 
same needs to be promptly reported to the sponsor or its designee and the IEC/ IRB and  must 
be reviewed and approved by the sponsor or its designee. Amendments to the protocol  must be 
submitted in writing to the investigator‚Äôs IRB/IEC for approval before subjects can be enrolled 
into an amended protocol.  
This protocol is to be followed exactly. To alter the protocol, amendments must be written, 
receive approval from the CRO an d/or from s ponsor, and receive IEC/IRB/ competent authority 
approval prior to implementation (if appropriate).  In the U nited S tates: Following approval, 
the protocol amendment(s) will be submitted to the Investigational New Drug application 
under which the study is being conducted.  
Administrative changes (not affecting the subject benefit/risk ratio) may be made without the need for a formal amendment. All amendments will be distributed to all protocol recipients, 
with appropriate instructions.  
11.2.2  Protocol Devi ations/Violations 
A deviation from the protocol is an unintended or unanticipated departure from the procedures 
or processes approved by the sponsor and the IRB/IEC and agreed to by the investigator. A significant deviation occurs when there is non-adherence to the protocol by the subject or 
investigator that results in a significant, additional risk to the subject. Significant deviations 
can include non- adherence to inclusion /exclusion criteria or non -adherence to FDA regulations 
or ICH GCP guidelines, and may lead to the subject being withdrawn from the study 
(Section  4.2). 
Page 269
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 91 All deviations from the approved protocol must be documented and notified to the 
sponsor/CRO at the earliest. The investigator should not deviate from the protocol, except for 
subject safety reasons, in which case the deviation must be reported to the sponsor/CRO 
immediately. The sponsor will not assume any resulting responsibility or liability from 
unapproved deviations. The investigator, according to applicable regulations and the 
IRB/IEC‚Äôs established procedures, will inform the IRB/IEC of protocol deviations.  
All instances where the requirements of the study protocol are not complied with, investigator/designee will file the protocol deviation and the same will be captured in a protocol 
deviation/violation log. Corresponding subjects may be withdrawn from the s tudy at the 
discretion of the sponsor/designee. Deviations from the study protocol should not be made other than as part of a protocol amendment. An amendment must be agreed upon by the 
sponsor, but not implemented until written IEC/IRB approval is obtained, except where 
necessary to eliminate an immediate hazard to study subjects or when the change(s) involves 
only logistical or administrative aspects. Protocol deviations/violations  and the reason why 
they occurred will be documented in the CSR. 
11.3 Study Term ination  
Although Dr. Reddy‚Äôs Laboratories  S.A. has every intention of completing the study, 
Dr. Reddy‚Äôs Laboratories  S.A. reserves the right to discontinue the study at any time for clinical 
or administrative reasons.  
11.4 Final Report 
Whether the study is completed or prematurely terminated, the sponsor will ensure that the CSR is  prepared and provided to the regulatory agency(ies) as required by the applicable 
regulatory requirement(s). The sponsor will also ensure that the CSR in marketing applications 
meet the standards of the ICH Harmonised T riparti te Guideline E3: Structure and C ontent of 
Clinical Study Reports. 
Data until Week 12 will be analyzed and reported in the final CSR after all subjects complete 
Week 12 visit (EOS/ET). The subsequent follow -up data from Week 12 to Week  26 will be 
reported as an addendum to the final CSR and for the data up to and including the Week 12 or ET visit.  
Page 270
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 92 Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the CSR. The investigat or will be provided reasonable access to 
statistical tables, figures, and relevant reports and will have the opportunity to review the complete study results.  
Upon completion of the CSR, the sponsor will provide the investigator with the full summary 
of the study results.  
Page 271
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 93 12 Financing and Insurance 
The sponsor shall carry an insurance policy to cover compensation of subjects‚Äô health injuries 
arising from the study. If a subject incurs a study -related injury, the subject may be treated (and 
other necessary measures taken) at the study site and/or another medical institution. If it is necessary to compensate for the treatment, the sponsor will cover the cost. The sponsor shall 
not impose on the subject the burden of proving the causal relation between the study and the 
injury.  
If any of the following is confirmed, the sponsor may refuse or restrict the payment of the compensation: 
1. A serious GCP or protocol deviation by the investigator or sub-i nvestigator (except 
deviation medically necessary to avoid an immediate hazard to the study subjects).  
2. Intentional act or negligence on the part of the investigator or sub- investigator or 
malpractice thereby.  
3. Injury caused by unlawful act or delinquency of a third party. 
4. Injury caused by intentional act or negligence of the subject. 
If compensation becomes necessary for a study -related injury, the site will promptly notify the 
sponsor and will cooperate with the sponsor and its insurer (or their legal representatives) in 
their handling thereof. 
Page 272
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 94 13 Reference List  
Bullock J, Rizvi SAA, Saleh AM , et al. Rheumatoid a rthritis: a brief overview of the treatment. 
Med Princ Pract. 2018;27(6):501‚Äì7. 
Clinical Trial Facilitation Group (CTFG). Recommendations related to contraception and 
pregnancy testing in clinical trials [internet]; 2014  Sep 15. Available from: 
https://www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf. Accessed 
02 Jul 2020. 
Cohen MD and Keystone E. Rituximab for rheumatoid arthritis . Rheumatol Ther. 
2015;2(2) :99‚Äì111.  
Doessegger L and Banholzer ML. Clinical development methodology for infusion -related 
reactions with monoclonal antibodies. Clin Transl Immunology. 2015;4(7):e39. 
Dr. Reddy‚Äôs Laborator ies S.A. DRL_RI. Investigator ‚Äôs Brochure  Version 7.0 (13 Sep  2019). 
Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the 
allergist. Ann Allergy Asthma Immunol. 2016; 117(2):115-20. 
Komatsu N and Takayanagi H. Inflammation and bone destruction in arthritis: syner gistic 
activity of immune and mesenchymal cells in joints . Front Immunol. 2012;3:77. 
MabThera¬Æ (rituximab): [summary of product characteristics]. Roche Registration GmbH. Germany; [cited 25  Mar  2020]. Available from: 
https://www.medicines.org.uk/emc/product/3801/smpc . Accessed 22 June 2020. 
Mikuls TR, Johnson SR, Fraenkel L,  et. al. American College of Rheumatology guidance for 
the m anagement of a dult patients with rheumatic disease during the COVID‚Äê19 pandemic. 
Arthritis Rheumatol. 2020. Available from:  
https://www.rheumatology.org/Portals/0/Files/ACR -COVID -19-Clinical -Guidance-
Summary -Patients -with-Rheumatic- Diseases.pdf. Accessed on 01  Jun 2020. 
Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87‚Äì100. 
Rituxan¬Æ (rituximab) Prescribing Information. 20 20. Available at: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705Orig1s5458lbl.pdf. 
Accessed 02 Jul 2020. 
Page 273
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 95 Sampson HA, Mu√±oz -Furlong A, Campbell RL, et al. Second symposium on the definition and 
management of anaphylaxis: summary report  ‚Äî second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med. 
2006;47(4):373-80. 
Singh JA, Saag KG, Brigdes SL Jr, et al.  2015 Americ an College of Rheumatology guideline 
for the treatment of r heumatoid a rthritis. Arthritis Rheumatol. 2016;68(1):1 -26. 
Page 274
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 96 14 Appendices 
14.1 Appendix 1 : Schedule of Events  
Table  14-1 Schedule of Events  
Study Period  Screening  
Visit   
Days -14 to 
0 Treatment Visit  Follow -Up Visits  EOS/E
Ta 
Visit  Additio
nal 
Follow -
up 
Visitm 
Study Week   0 
(Day 1)  2 
(Day 
15) 4 8 12 26 
Visit Window   +1 day  +1 day  ¬±7 days  
Informed consentb X - - - - - - 
Inclusion/exclusion 
criteriac X Xk - - - - - 
Medical and surgical 
history  X - - - - - - 
Prior and ongoing 
medication  X - - - - - - 
Demographics  X - - - - - - 
TB screening  (if 
required)d X - - - - - - 
Viral disease screeninge X - - - - - - 
Physical examinationf X X X X X X X 
Vital signs 
measurementsg X X X X X X X 
12-lead ECG  X - - - - X X 
Pregnancy testh X X X X X X X 
Clinical laboratory 
assessmentsi X Xl X X X X X 
Randomization  - X - - - - - 
Study treatment  
administration  - X X - - - - 
Adverse events  X X X X X X X 
Immunogenicityj - X X X X X - 
Blood sample for 
estimation of rituximab 
concentration  - X X X X X - 
Concomitant medications  - X X X X X X 
Page 275
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 97 Abbreviations: ADA , anti-drug antibody ; ECG , electrocardiogram; EOS , end of study ; ET, e arly termination ; 
EU-rituximab, European Union approved rituximab (MabThera); HBcAb , hepatitis B core antibody; HBsAg , 
hepatitis B surface antigen; HCV , hepatitis C virus; HIV , human immunodeficiency virus; 
IgG, immunoglobulin  G; IgM, immunoglobulin  M; NAb , neutrali zing antibody ; TB, t uberculosis ; 
US-rituximab, United States -licensed rituximab (Rituxan) . 
Note: For assessments related to COVID -19, see Section  3.2 of the protocol.  
a All subject s completing the study at Week  12 or  those discontinuing the study at any time will attend an 
EOS/ET visit. The allowable window for the EOS/ET visit is ¬±7 days.  
b Informed consent must be obtained prior to undergoing any protocol -specific procedure.  
c All eligibility criteria must be met before a subject is randomized to study treatment . Subjects must have 
received at least 1 full course comprising two 1000 mg infusion  of either US- rituximab at least 16  weeks or 
EU-rituximab at least 24  weeks prior but not more than 15 months prior to the day of randomization visit.  
d T uberculosis  testing is to be done only if it is required by local regulations or practice.  
e The following tests are to be conducted by each site‚Äôs local laboratory: HBsAg , HBcAb, HCV , HIV , serum 
IgG and IgM . 
Note: For HBcAb, site is requested to perform HBcAb IgG and HBcAb IgM.  If any of these 2 results is 
positive, then the subject will be considered as screen failure.  
f Complete physical examination will be performed at all visits . Height will be recorded at screening only.  
g Body temperature  (oral) , blood pressure, heart rate, and respiration rate will be recorded at each visit. Vital 
signs will be monitored every 30  minutes  (¬± 5 minutes)  during the course of the treatment administration or 
more frequently as necessary.  
h Subjects who are WOCBP  will have a serum pregnancy test at the  screening visit, Week  12 (EOS/ET) , and 
Week  26 (additional follow -up) and a urine pregnancy test on Day 1 prior to randomization and Day  15 
(before dosing) , Week  4, and Week 8 visits. All tests will be performed by the local laboratory according to 
local practice. 
i Clinical laboratory assessments (hematology/ biochemistry/urinalysis) will be performed by the local 
laboratory. See Section 6.3.4 for the list of tests . 
j Plasma samples for detection of ADA  will be collected before the administration of study treatment on Day  1 
and Day  15 (p referably within 30  minutes prior to infusion). Additional samples for detection of ADA will 
be collected at Weeks 4, 8, and 12 (EOS/ET).  Samples that are confirmed posit ive for ADA will be further 
tested for titer and NAb. Details are provided in Section 6.2. 
k Viral disease screening (HBsAg, HBcAb, HCV , and HIV), serum IgG  and IgM , and TB screening will not be 
repeated on Day  1 of the study.  
l Clinical laboratory assessments scheduled on Day  1 can be performed 1 day prior to dosing.  
m Additional follow -up visit will be conducted at Week  26 to e valuate safety and to  perform a serum pregnancy 
test in WOCBP.  
Page 276
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 98 14.2 Appendix 2: Classification of Functional Status in Rheumatoid 
Arthritis  
Table 14-2: Classification of Functional Status in Rheumatoid Arthritis  
Class I  Complete functional capacity with ability to carry on all usual duties without handicaps  
Class II  Functional capacity adequate to conduct normal activities despite handicap of discomfort 
or limited mobility of one or more joints  
Class III  Functional capacity adequate to perform only few or none of the duties of usual 
occupation or of self -care 
Class IV  Largely or wholly incapacitated with patient bedridden or confined to wheelchair, 
permitting little or no self -care 
Page 277
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 99 14.3 Appendix 3: Protocol Amendment 
14.3.1  Protocol Amendment 1 ‚Äì Protocol Version 2.0, Dated 12 Aug 2019  
14.3.1.1  Overview of Changes 
Summary of significant changes includes the following: 
1. Updated exclusion criterion 2 for clarity.  
2. Added Exclusion Criterion 18. Subjects with hypogammaglobulinemia (low IgG ) are 
immunocompromised and more susceptible for both infections and side effects ; hence, 
such subjects should be excluded.  
3. ‚ÄòSection 5.4.1 Packaging‚Äô has been reworded for better clarity . Further details will be 
captured in Pharmacy Manual/other appropriate plan. Sentence modified from: 
‚ÄúRituximab concentrate for solution for infusion will be packaged as blinded supplies 
in which the external packaging (carton) for all products will appear  identical and 
identified with a unique container number.‚Äù 
To 
Rituximab concentrate for solution for infusion will be packaged in a carton or kit. 
4. Added following text in Section 6.1 of Schedule of Assessment in order to clarify 
unscheduled visit data capt uring: ‚Äú If any unscheduled visits happens at any time during the 
study, visit details/appropriate data including reason will be captured in the electronic case report forms (eCRF). ‚Äù  
5. Added assessment of IgG (Section  6.1.1) in- line with addition of new Exclusion Criterion 
18 to exclude the subjects with low IgG. 
6. Added clarification for estimation of rituximab concentration in Section  3.1.2 and 
Section  6.2.1, t ime matched blood samples for estimation of rituximab concentration were 
added to aid in subsequent data interpretation  as and if needed . Relevant procedures (i.e. 
time matched blood sample collection and blood loss for estimation of rituximab concentration) are added in Section 6.1.2, Section  6.1.3, Section  6.1.4, Section 6.5, and 
Appendix 1. 
7. Other administrative and minor formatting changes were made throughout the protocol for 
consistency.  
Page 278
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 100 14.3.1.2   Changes to the Protocol Text 
In this section, all affected protocol sections are detailed; the sequence of the sections follows 
the structure of the original protocol. Additions to the study protocol are shown in bold and 
deletions are shown in strike through  text. Corrections of obvi ous typing errors or omissions 
are not highlighted. 
Protocol Synopsis  
‚Ä¢ Exclusion criteria  
2. Subjects with human immunodeficiency virus  (positive HIV1Ab or HIV2Ab), 
hepatitis B virus and/or hepatitis C virus infection , including those with 
positive results in the viral disease screening.  
18. Subject with serum IgG <  lower limit of normal 
List of Abbreviations 
LLN  Lower limit of normal  
Pharmacodynamics (Section 1.1.1.2) 
Total serum Ig levels, immunoglobulin M (IgM), immunoglobulin G (IgG), and 
immuno globulin A (IgA) were decreased at 6 months with the largest change observed in IgM. 
At Week  24 of the first course of rituximab  treatment, small proportions of patients experienced 
decrease in IgM (10%), IgG (2.8%), and IgA (0.8%) levels below the lower l imit of normal . 
(LLN) . In the experience with rituximab  in RA patients during repeated rituximab  treatment, 
23.3%, 5.5%, and 0.5% of patients experienced decreases in IgM, IgG, and IgA, respectively 
concentrations below the lower limit of normal LLN at any time after receiving rituximab . The 
clinical consequences of decrease in Ig levels in RA patients treated with rituximab  are unclear 
(Dr. Reddy‚Äôs Laboratories IB).  
Rationale of Study Design (Section 3.1.2)  
A validated enzyme linked immunosorbent assay will be used to test ADA, titer and NAb by specialist laboratories (sponsor designated laboratories) in this study.  
Along with immunogenicity sample, a time matched blood sample (approximately 5 mL) 
will be collected for the estimation of rituximab concentration. The evaluation of the 
Page 279
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 101 samples will be performed to interpret safety and/or immunogenicity  data appropriately, 
if needed.  
Exclusion criteria (Section 4.1.2):  
Subjects meeting any of the following criteria must not be enrolled in the study:  
2. Subjects with human immunodeficiency virus  (positive HIV1Ab or HIV2Ab), 
hepatitis B virus and/or hepatitis C virus infection , including those with 
positive results in the viral disease screening  (Sec tion 6.1.1). 
18. Subject with serum IgG < LLN  
Schedule of Assessments (Section 6.1) 
The investigator may plan unscheduled visits  schedule visits (unplanned visits) in addition to 
those listed on the schedule of activities, in order to conduct evaluations or assessments 
required to protect the well- being of the subject. If any unscheduled visits happen at any 
time during the study, visit details/appropriate data inclu ding the reason will be collected  
in the eCRF.  
Packaging (Section 5.4.1) 
Rituximab concentrate for solution for infusion will be packaged in a carton or kit  as blinded 
supplies in which the external packaging (carton) for all products will appear identical and 
identified with a unique container number. 
Screening Period (Day  14 to 0) (Section 6.1.1)  
Screening procedures and assessments will be as follows:  
The proposed chronological order of the assessments below should be followed. 
14. Serum Immunoglobulin ( IgG) 
Treatment Period (2 Weeks) (Section 6.1.2)  
Study Day 1 (Week 0, Baseline Visit)  
4. Clinical laboratory assessments: a blood sample will be taken for hematology and 
biochemistry; urinalysis will also be performed (See Section 6.3.4 for the list of 
clinical laboratory assessments).  
Page 280
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 102 Note: Viral disease screening (HBsAg, HBsAb  HBcAb, HCV , HIV), and serum 
IgG and TB screening will not be repeated on Day 1 of the study. On Day 1, 
clinical laboratory assessments can be performed 1  day pri or to dosing.  
7. Collect a time matched blood sample (approximately 5 mL) for the estimation 
of rituximab concentration.  
Study Day 15 (Week 2 + 1 Day)  
5. Collect a time matched blood sample (approximately 5 mL) for the estimation 
of rituximab concentration . 
Follow -Up Period (10 Weeks) (Section 6.1.3)  
Week 4 ¬± 7 Days 
5. Collect a time matched blood sample (approximately 5 mL) for the estimation 
of rituximab concentration.  
Week 8 ¬± 7 Days 
5. Collect a time matched blood sample (approximately 5 mL) for the estimation 
of rituximab concentration.  
End of Study/Early Termination Visit (at Week 12 ¬± 7 Days) (Section 6.1.4) 
EOS/ET assessments are as follows:  
6. Collect a time matched blood sample (approximately 5 mL) for the estimation of rituximab concentration.  
Immunogenicity Sampling (Section 6.2.1)  
Whole blood samples (approximately 10 mL) will be collected and processed to obtain approximately 4 mL of plasma for ADA (including titer and NAb) detection at each time point. 
Samples should be proces sed as per detailed instructions in the laboratory manual for collection 
by the central laboratory. The samples will be shipped to laboratories for ADA titer and NAb analysis by the central laboratory as detailed in the laboratory manual. 
Page 281
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 103 Along with the immunogenicity sample, a time matched blood sample (approximately 5 
mL) will be collected for the estimation of rituximab concentration. The evaluation of the 
samples will be performed to interpret safety and/or immunogenicity  data appropriately, 
if needed.  
The central laboratory shipment address and assay laboratories contact information will be 
provided to the investigator prior to or during the initiation of the study. 
Clinical Laboratory Assessments (Section  6.3.4 ) 
Clinical laboratory assessments will be performed as indicated in Table  14-1. Hematology, 
biochemistry, and urinalysis will be conducted at screening, on Day 1, Day 15, and at  Weeks 4, 
8, and 12 (EOS/ET) visits . Serum pregnancy test  will be conducted at screening and Week 12 
visit. Urine pregnancy test will be conducted on Day 1 prior to randomization and Day 15 
(before dosing),  at Weeks 4 and 8 visits.  
The following parameters will be assessed:  
Serum IgG  
Blood Loss During the Study (Section 6.5) 
For the safety evaluation, approximately 10 mL of blood will be withdrawn from the subjects 
at each time point. A total of approximately 110  135 mL of blood will be collected per subjec t 
during the study for immunogenicity, for estimation of rituximab concentration  and safety 
evaluation as mentioned in Table  6-1. 
Page 282
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 104 Table 6 -1 Blood Loss Du ring the Study  
Abbreviations: ADA=anti -drug antibody; NAb=neutralizing antibodies  
Note: For safety evaluation, more than 10 mL of blood can be withdrawn based on the site/local laboratory 
practice and will not be considered as deviation.  
 
Appendix 1: Schedule of Events (Section 14.1)  
Table 14-1 Schedule of Events  
Study Period  Screening  
Visit   
Days -14 to 0 Treatment Visit  Follow -Up Visits  EOS/ETa 
Visit  
Study Week   0 
(Day 1)  2 
(Day 15)  4 8 12 
Visit Window   +1 day  +1 day  ¬±7 days  
Viral disease screeninge X      
Pregnancy testh X X X X X X 
Immunogenicityj  X X X X X 
Blood samples for 
estimation of rituximab 
concentration   X X X X X 
Concomitant medications   X X X X X 
e HBsAg , HBcAb, hepatitis C virus, and HIV , and Serum IgG  to be conducted by each site‚Äôs local laboratory.  
h Subjects of childbearing potential will have a serum pregnancy test at the screening visit and a urine pregnancy 
test on Day 1 prior to randomization and Day  15 (before dosing),  and at Week  2, Week 4 and Week 8 visits. 
A serum pregnancy test will be repeated at EOS/ET visit. All tests will be performed by the local laboratory 
according to local practice.  
k Viral disease screening (HBsAg, HBsAb  HBcAb , HCV , and HIV), serum IgG  and TB screening will not be 
repeated on Day 1 of the study.  Time Points  Safety Evaluation 
(Laboratory) ADA and NAb 
Evaluation  For estimation 
of rituximab 
concentration 
(Approx.)  Total V olume of 
Blood Loss  
Screening  10 mL  -  10 mL  
Week 1/Day 1  10 mL  10 mL  5 mL  20 25 mL 
Week 2/Day 15 10 mL  10 mL  5 mL 20 25 mL 
Week 4  10 mL  10 mL  5 mL  20 25 mL 
Week 8  10 mL  10 mL  5 mL  20 25 mL 
Week 12 10 mL  10 mL  5 mL  20 25 mL 
Total volume of blood loss  60 mL  50 mL  25 mL  110 135 mL 
Page 283
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 105 14.3.2  Protocol Amendment 2 ‚Äì Protocol Version 3.0, Dated to be added 
The overall reason for this amendment is to address feedback from Paul Ehrlich Institute (P EI), 
Medical Regulatory Authority, Germany . Further to these changes , minor revisions for clarity, 
formatting, abbreviations, and spelling changes have been  made throughout the document. 
14.3.2.1  Overview of Changes 
Summary of significant changes includes the following: 
‚Ä¢ The duration of study is extended by 6 months post treatment. The study now includes an 
additional follow -up visit at Week  26 (24 weeks [6  months] after the last study treatment 
administration on Day 15) . At the additional follow -up visit (Week 26), safety will be 
evaluated  and a serum pregnancy test will be performed in WOCBP. Further it is also 
clarified in the protocol that subjects need to re -consent if they want to continue 
participating in the study after Week  12 through Week 26. Additional text/clarity has been 
included when a subject requires rescue therapy/re-dosing of rituximab after Week 12. 
o New text has been added and existing text has been revised as applicable throughout the protocol, with the following affected sections: Protocol Synopsis (Study Design and 
Estimated Study Duration sections), Section 3.1.1 (Description), Section  3.1.2 (Rationale 
of Study Design), Section 3.1.4 (End of Study), Section 4.2 (Withdrawal of Subjects From Study Treatment and/or Study), Section 4.2.2 (Handling of Withdrawals), Section 5.7 
(Blinding), Section  6.1.5 (Additional Follow -up Visit [Week  26]), Section 6.3.1.2 
(Recording of Adverse Events), Section 6.3.4 (Clinical Laboratory Assessments), Section  6.5 (Blood Loss During the Study), Section 11.4 (Final Report), and Appendix 1 
(Schedule of Events). 
Reason: Above changes ha ve been done to address recommendations from P EI, Medical 
Regulatory Authority, Germany to follow subject s for safety in line with SmPC and for further 
monitoring of contraception in WOCBP until 6 mo nths post -dose considering the longer half -
life of Rituximab (approximately 20  days). 
‚Ä¢ Clarified  that the final CSR will be prepared after the EOS (Week  12) is achieved by all 
subjects. Data for the time period from Week  12 through Week 26 (additional follow -up) 
will be presented as an addendum to the final CSR.  
Page 284
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 106 o Text regarding this clarification revised in the following sections: Section  3.1.1 
(Description), Section 5.7 (Blinding), and Section  11.4 (Final Report). 
Reason: Changes ha ve been made in accordance with the changes of extending the study up to 
26 weeks (as mentioned above) as all the data required for the primary objective would have 
been collected by W eek 12. 
‚Ä¢ Detailed information regarding study conduct and contingency measures to be taken for smooth functioning of the study during the COVID -19 pandemic are added. In addition, 
benefit- risk assessment of rituximab treatment during the COVID -19 pandemic have also 
been discussed in the protocol. 
o New section (Section  3.2 [Study Conduct During the COVID -19 Pandem ic]), including 
subsections (Section  3.2.1 [Benefit -Risk Assessment of Rituximab Treatment During the 
COVID- 19 Pandemic] and Section  3.2.2 [Contingency Measures Taken During the 
COVID- 19 Pandemic]) are added. 
Reason: Above changes ha ve been made to describ e the risk-benefit assessment of the study 
conduct along with risk mitigation measures and to describe contingency measures for the 
ongoing COVID 19 pandemic, as also recommended by P EI, Medical Regulatory Authority, 
Germany . 
‚Ä¢ Exclusion Criterion #6 has been revised in Protocol Synopsis and Section 4.1.2 (Exclusion 
Criteria) to update the requirement of historical ‚Äúsevere‚Äù hypersensitivity to US -rituximab 
or EU -rituximab or any of its excipients requiring drug discontinuation to any severity of 
hypersensitivity to these treatments  or excipients. 
Reason: Above change has been made to avoid the risk of hypersensitivity reaction in the 
subject as an additional safety measure.  
‚Ä¢ Exclusion Criterion #16 updated to include definition of WOCBP and highly effective birth 
control measures per the CTFG 2014 guidelines  in Protocol Synopsis and Section 4.1.2 
(Exclusion Criteria). 
Reason: Above change has been made to define WOCBP and to describe highly effective measures of birth control as per the CTFG 2014 guidelines. This change is also considered for 
better clarity  and in line with the recommendation from P EI, Medical Regulatory Authority, 
Germany.  
Page 285
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 107 ‚Ä¢ Exclusion Criterion #17 related to subjects who are men involved in any sexual intercourse 
that could lead to pregnancy is updated in Protocol Synopsis and Section 4.1.2 (Exclusion 
Criteria) to clarify that sexually active male subjects ( unless permanently  sterile by bilateral 
orchidectomy) , who do not agree to use 1 of the highly effective methods of birth control 
during treatment and for at least 12  months after the last administration of study treatment, 
will be excluded from the study. 
Reason: Above cha nge has been made to describe highly effective measures of birth control as 
per the CTFG, 2014 guidelines and for better clarity and in line with the recommendation from 
PEI, Medical Regulatory Authority , Germany . 
‚Ä¢ Clarified that if a subject withdraws consent for further study treatment, but not for study participation, the subject can continue further visits and data can continue to be collected until Week  26. However, if a subject withdraws consent for further participation in the 
study there will be no f urther data collection and the subject will be discontinued from the 
study. Subjects need to re -consent to continue participating in the study after Week 12 
through Week 26, If a subject does not re -consent, then his/her study data up to Week 12 
will be collected and the subject will be discontinued from the study.  
o Text added for this clarification in Protocol Synopsis (Study Design), Section  3.1.1 
(Description), Section 4.2 ( Withdrawal of Subjects From Study Treatment and/or the 
Study), Section  4.2.1 (Reas ons for Withdrawal/Discontinuation), and Section 4.2.2 
(Handling of Withdrawals)  
Reason: Above change has been made to categorize withdrawal criteria (i.e. consent withdrawal for further study treatment or for further study participation) and to make it un iform 
with the section 4.2.2 (Handling of Withdrawals). 
‚Ä¢ Text in Section 4.2.2 (Handling of Withdrawals) revised to emphasize that subjects can 
take their own independent decision to withdraw from study treatment and/or study participation at any time.  
Reason: Above change has been made to emphasize that subjects can take their own independent decision to withdraw from study treatment and/or study participation. Moreover , 
text has been revised  to add the clause for the consent withdrawal at Week 12 based on the 
earlier change of extending study duration up to Week 26, post-dose. 
Page 286
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 108 ‚Ä¢ Clarified that MTX and folic acid, which are background medications in the study, should 
be used in accordance with the guidelines specified in the local labels. Also,  clarification 
has been provided that f olinic acid at the same dose of folic acid , can be given in place of 
folic acid if it is allowed by the local label.  A note has been  added in protocol synopsis 
(Study Treatment, Dosage, and Route of Administration) and Section 5.9.1 (Background 
Medications).  
Reason: Above change has been made in line with the recommendation from PEI, Medical 
Regulatory Authority, Germany and for better clarity to the investigators   
‚Ä¢ Comp lete physical examination will be performed now at all study visits and not as 
indicated only at screening and EOS/ET visits in the Schedule of Assessments of the earlier 
protocol (Version  2.0, Amendment  1).  
o Text updated in the following sections: Section  6.1 (Schedule of Assessments [including 
relevant subsections]) and Appendix  1 (Schedule of Events; footnote ‚Äúf‚Äù). 
Reason: Above change has been made for better clarity and for uniformity across the document . 
‚Ä¢ Information regarding immunological testing in humans has been included in Section 6.2.2 
(Immunogenicity Assay). 
Reason: Above change has been made to add more information about the testing/methods of primary endpoints. 
‚Ä¢ Detailed definitions of IRRs and hypersensitivity reactions is added in Section 6.3 (Safety 
Assessments).   
Reason: Above change has been made to guide the investigator while differentiating IRRs , 
hypersensitivity reactions and/or anaphylaxis. 
‚Ä¢ Clarified that all ongoing SAEs should be followed up until resolution or stabilization or 
until a pre -defined outcome is reached, whereas all ongoing nonseriou s AEs should be 
followed up until resolution or stabilization or the EOS/ET visit, whichever occ urs first, 
except any ongoing treatment -related nonserious AEs that should be followed until that  AE 
is stabilized, resolved, or, in the investigator's opinion, the AE is unlikely to resolve due to 
the subject's underlying condition. 
o Text updated and note has been added in Section 6.3.1.2 (Reporting of Adverse Events). 
Page 287
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 109 Reason: Above change s have  been made for better clarity and in line with the recommendation 
from PEI, Medical Regulatory Authority, Germany . 
‚Ä¢ Clari fication note has been provided for assessmen t of adverse events  outcome in 
Section  6.3.1.4 (Assessment of Causality).  
Reason: Above change has been made for better clarity to the investigator.  
‚Ä¢ Absolute neutrophil count is added to the list of hematology parameters to be assessed in 
the study. List of hematology parameters to be assessed in the study are provided in 
Section  6.3.4 (Clinical Laboratory Assessments) updated. 
Reason: Above change has been made to clarify and to emphasize safety evaluation i.e. late 
neutropenia and also in line with earlier changes.  
‚Ä¢ Serum FSH testing will be performed in postmenopausal women. 
o Text added in Section 6.3.4 (Clinical Laboratory Assessments).  
Reason: Above change has been made in line with earlier changes and per the CTFG 
guidelines 2014. 
‚Ä¢ Clarification note is added for HBcAb  evaluation 
o A clarification note is added in the S ection 6.1.1 ( Screening Period [ Days -14 to 0]) , 
Section  6.1.2 ( Treatment Period [ (2 Weeks ]), Section  6.3.8 (Viral Disease Screening)  and 
in Appendix 1 (Schedule of Events; footnote ‚Äúe‚Äù).  
Reasons: Above change s have been done for better clarity to the investigators. 
‚Ä¢ Additional Serum Immunoglobulin  evaluation ( IgM) is added in the S ection  6.1.1 
(Screening Period [Days -14 to 0]) , Section 6.1.2 (Treatment Period [2 weeks]; Study 
Day 1 [Week  0, Baseline visit]), Section  6.3.4 (Clinical Laboratory Assessments), and in 
Appendix 1 (Schedule of Events; footnote ‚Äúe‚Äù and footnote ‚Äúk ‚Äù) 
Reasons: Above change has been made in line with the recommendation from PEI, Medical 
Regulatory Authority, Germany  
‚Ä¢ All references to legally authorised or legally acceptable representatives or subject‚Äôs legal 
guardian and any equivalents ha ve been removed. Moreover, it is further clarified that the 
Page 288
Dr. Reddy‚Äôs Laboratories  S.A. DRL_RI  
Protocol : Version 3.0 Amendment 2 10 Jul 2020 
Page 110 study sites are advised to follow local or country- specific guidelines while obtaining 
consent from the subject.  
o Text added in Section 9.1 ( Independent Ethics Committee or Institutional Review Board ), 
Section  9.3 (Subject Information and Consent). Section 10.1 (Confidentiality).  
Reason: Above change has been made to remove all references of legally authorised or legally 
acceptable representatives or subject‚Äôs legal guardian and any equivalents from the protocol 
with consideration that only those subjects who are capable of providing informed consent will 
be included in this clinical study . This change has also been done in line with the 
recommendation from PEI, Medical Regulatory Authority, Germany . 
‚Ä¢ The sponsor contact details on the title page of this protocol are updated. 
Reasons: Administrative change  
Minor revisions for clarity, formatting, abbreviations, and spelling changes have been  made 
throughout the document. 
Page 289
  DRL_RI 
Protocol: RI-01-007 Version 3.0 Amendment 2  10 Jul 2020 
Page 1 
 Protocol Clarification Letter #1 
22 Jul 2020 
To Whom So Ever It May Concern 
 
This letter is to inform you about an typographical error in clinical study protocol of RI-01-007 
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the 
Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to 
Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan¬Æ or MabThera¬Æ 
Version 3.0 Amendment 2, dated 10 Jul 2020. The following sections require further 
clarification:  
Protocol Amendment 2  Protocol Version 3.0, Dated to be added  is mentioned in Table of 
contents ( Section 14.3.2 ) and in the title of Section 14.3.2 which should be read as Protocol 
Amendment 2  Protocol Version 3.0, Dated 10 Jul 2020 . 
This letter will serve as documentation of this typographical change to protocol RI-01-007. If 
at a later date the protocol is amended, this change will be incorporated into the document at 
that time. 
 
Sincerely, 
     
    
  
  
 
 
Page 290
CI